US Pat. No. 10,889,619

METHODS FOR TREATING CANCER

SLH Innovations LLC, Han...

1. An isolated deoxyribonucleic acid (DNA) molecule that encodes a peptide, wherein the peptide comprises amino acid sequence PPLSQTSFAEYWNLLSP (SEQ ID NO: 2).
US Pat. No. 10,889,875

GRAIN ORIENTED ELECTRICAL STEEL SHEET, METHOD FOR MANUFACTURING GRAIN ORIENTED ELECTRICAL STEEL SHEETS, METHOD FOR EVALUATING GRAIN ORIENTED ELECTRICAL STEEL SHEETS, AND IRON CORE

JFE STEEL CORPORATION, T...

1. A method for evaluating a grain oriented electrical steel sheet having a steel sheet and a forsterite film formed on a surface of the steel sheet to estimate adhesion between the forsterite film and the surface of the steel sheet, the method comprising:irradiating the surface of the grain oriented electrical steel sheet with an electron beam;
dispersing a consequent emission into a spectrum; and
evaluating adhesion between the forsterite film and the surface of the steel sheet using a specific correlation between predetermined adhesion values and at least one of (i) an intensity of at least one of emission peak A and emission peak B observed at 380 nm to 600 nm wavelengths, and (ii) an intensity ratio Ia/Ic, Ib/Ic, or (Ia+Ib)/Ic,
where Ia is an intensity of emission peak A, Ib is an intensity of emission peak B observed at a longer wavelength than the emission peak A, and Ic is an intensity of emission peak C observed at a wavelength in a range of 600 nm to 665 nm.
US Pat. No. 10,888,594

GENETICALLY ENGINEERED VACCINIA VIRUSES

National University Corpo...

1. A vaccinia virus comprising a polynucleotide encoding interleukin-7(IL-7); and a polynucleotide encoding interleukin-12(IL-12), wherein the vaccinia virus is deficient in the function of vaccinia virus growth factor (VGF) or deficient in the function of O1L, and wherein the vaccinia virus is oncolytic against human cancer cells.
US Pat. No. 10,889,620

SOLID STATE FORMS OF LINACLOTIDE

NOVETIDE LTD., Haifa Bay...

1. Crystalline Form III of Linaclotide characterized byan X-ray powder diffraction pattern having peaks at 5.1, 7.7, 10.3, 14.8 and 22.0 degrees two theta ±0.2 degrees two theta; and optionally further characterized by data selected from one or more of the following:
(i) an X-ray powder diffraction pattern as depicted in FIG. 1; or
(ii) a solid state 13C NMR having peaks at 18.5, 43.0, 49.9, 52.4, 56.5, 61.9, 115.7, 133.8, 169.1, 171.5 ppm±2 ppm; or
(iii) combinations of this data.
US Pat. No. 10,889,876

NON-HEAT TREATED WIRE ROD HAVING EXCELLENT COLD WORKABILITY AND MANUFACTURED METHOD THEREFOR

POSCO, Pohang-si (KR)

1. A non-heat treated wire rod, comprising:carbon (C): 0.15 wt % to 0.30 wt %, silicon (Si): 0.05 wt % to 0.3 wt %, manganese (Mn): 1.0 wt % to 2.0 wt %, chrome (Cr): 0.45 wt % or less (excluding 0%), phosphorus (P): 0.02 wt % or less, sulfur (S): 0.02 wt % or less, soluble aluminum (sol. Al): 0.01 wt % to 0.05 wt %, niobium (Nb): 0.005 wt % to 0.02 wt %, vanadium (V): 0.05 wt % to 0.2 wt %, nitrogen (N): 0.008 wt % or less, iron (Fe) as a remainder; and unavoidable impurities,
wherein the non-heat treated wire rod satisfies Formula 1 and Formula 2, when hardness of the wire rod, measured in a ½d position and a ¼d position in the diameter direction of the wire rod, are Hv,1/2d(Hv) and Hv,1/4d(Hv), respectively,
(Hv,1/2d+Hv,1/4d)/2?240  [Formula 1]
Hv,1/2d/Hv,1/4d?1.2  [Formula 2]
where d is a diameter of a wire rod.
US Pat. No. 10,888,595

APPARATUS FOR PREPARATION OF PHARMACOLOGICALLY-RELEVANT COMPOUNDS FROM BOTANICAL SOURCES

1. A method for distilling an essential oil from raw cannabis comprising:providing a distillation vessel having a gravity drain;
placing a portion of fresh cannabis in the distillation vessel;
heating the distillation vessel in a microwave oven under at least a partial continuous vacuum for a time period and at a power level sufficient to substantially dry and decarboxylate the cannabis;
as the distillation vessel is heated, continuously draining accumulated liquid and vapor under at least a partial continuous vacuum from the distillation vessel into a condenser;
draining a resulting distillate from the condenser into an oil/water separator capable of maintaining the at least partial continuous vacuum; and
draining a resulting essential oil layer into a collection vessel, as an aqueous layer is pumped from the oil-water separator in a continuous flow.
US Pat. No. 10,888,852

FCC CATALYST ADDITIVE AND BINDER

ALBEMARLE CORPORATION, C...

1. A process for the preparation of a catalyst additive comprising the following steps:a. mixing an alumina source with water to make a slurry;
b. adding to the slurry of step (a) an amount of P2O5 source;
c. the slurry of step (b) is then stirred and reacted at a temperature above 5° C. but not higher than 60° C. and under time conditions to form an aluminum phosphate binder;
d. adding to the aluminum phosphate binder a zeolite, an amount of silica binder and an amount of clay; and
e. spray-drying the slurry of step (d) to form catalyst additive particles.
US Pat. No. 10,889,621

COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO EPHRIN SIGNALING WITH CUPREDOXINS

THE BOARD OF TRUSTEES OF ...

1. A method comprising administration of a composition comprising:an amino acid sequence that binds to either an ephrin or an Eph receptor and has been modified, the amino acid sequence is a truncation of cupredoxin consisting of a sequence selected from the group consisting of: SEQ ID NO: 18, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 34, and
the modification is selected from the group consisting of: glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation, ADP-ribosylation, amidation, acetylation, polyethylene glycol (PEG) modification, and phosphorylation; and
a pharmaceutically acceptable carrier.
US Pat. No. 10,888,596

METHOD OF PREPARING CANNABIS EXTRACTS

Cold Baked LLC, Colorado...

1. A method of preparing a cannabis extract for a shatter product comprising the steps of:freezing dehydrated cannabis plant material;
placing the frozen plant material into a vessel of a chamber having a vessel and a gasket;
integrating the chamber with a chiller column;
pumping solvent gas into the chamber;
filtering the solvent gas through the gasket and into the vessel of the chamber and through the plant material in the vessel of the chamber;
collecting the filtered solvent gas in a collection vessel;
purifying the filtered plant material by recovering the solvent gas from the collection vessel by means of applying heat to the collection vessel, boiling off the solvent gas and pumping recovered solvent gas back into a gas holding tank;
scraping a filtered plant material cookie from the vessel of the chamber into another collection vessel;
chopping the cookie into a powder;
heating the powder under vacuum pressure between about 70° F. and about 110° F. from about 15 minutes to about 48 hours; and
heating the powder at atmospheric pressure with a heat gun that is passed over the powder to apply heated air from about 160° F. to about 210° F. to the powder until a clear and transparent shatter product results.
US Pat. No. 10,889,622

PEPTIDE LIGASE AND USE THEREOF

Oxford University Innovat...

1. A polypeptide comprising:a) an amino acid sequence as set forth in SEQ ID NO: 1; or
b) an amino acid sequence with at least 80% sequence identity to a sequence as set forth in SEQ ID NO: 1, wherein said amino acid sequence comprises a glutamic acid at position 61 and one or more of the following:
1) proline at position 66;
2) proline at position 95;
3) glycine at position 96; and
4) valine at position 97,
wherein the specified amino acid residues are at positions equivalent to the positions in SEQ ID NO: 1 and wherein said polypeptide is capable of promoting the formation of an isopeptide bond between the lysine residue at position 9 of SEQ ID NO: 2 and the asparagine residue at position 17 of SEQ ID NO: 3.
US Pat. No. 10,889,878

ALLOY MATERIAL, CONTACT PROBE, AND CONNECTION TERMINAL

NHK Spring Co., Ltd., Yo...

1. An alloy material comprising:a composition, in a composition range of an alloy of silver (Ag), palladium (Pd), and copper (Cu), the composition containing 20 to 30 wt % of Ag, 35 to 55 wt % of Pd, and 20 to 40 wt % of Cu, wherein
the composition as a base is
added with tin (Sn) in a range of 0.5 to 2.5 wt %,
added with chromium (Cr) in a range of 0.1 to 1.0 wt %, and
added with 0.01 to 0.1 wt % of either one of or a combination of iridium (Ir) and ruthenium (Ru).
US Pat. No. 10,888,597

COMPOSITION FOR TREATING BRAIN STROKE

ENLIVEN BIOTECHNOLOGY CO,...

1. A method for treating ischemic brain stroke, comprising:administering to a subject in need thereof an effective amount of a composition, comprising:
an extract of a mixture,
wherein the mixture comprises Chuanxiong Rhizoma, Rhei Radix et Rhizoma, Angelicae Dahuricae Radix, Scutellaria baicalensis, Coptidis Rhizoma, Gardeniae Fructus, and Carica papaya.
US Pat. No. 10,888,598

EFFICIENT LIPID DELIVERY TO HUMAN TEAR FILM USING A SALT-SENSITIVE EMULSION SYSTEM

ALLERGAN, INC., Irvine, ...

1. A low salt ophthalmic pharmaceutical composition useful for the treatment of dry eye or keratoconjunctivitis comprising a sub-micron emulsion, a polymer lubricant, and a salt-sensitive viscosity modulating polymer, wherein said sub-micron emulsion comprises a surfactant and a therapeutic lipid consisting of castor oil.
US Pat. No. 10,888,855

SILICON-TITANIUM DIOXIDE-POLYPYRROLE THREE-DIMENSIONAL BIONIC COMPOSITE MATERIAL BASED ON HIERARCHICAL ASSEMBLY AND USE THEREOF

JIANGNAN UNIVERSITY, Wux...

1. A silicon-titanium dioxide-polypyrrole three-dimensional bionic composite material based on hierarchical assembly, comprising an ordered hierarchy (Si/TiO2/PPY) of monocrystalline silicon (Si), titanium dioxide (TiO2) and polypyrrole (PPY),wherein Si is 100-type monocrystalline silicon with a tapered microstructure surface and is a P-type semiconductor, and has compactly arranged silicon cone structure of tetragonal pyramids with a height of 4-10 ?m;
TiO2 is TiO2 nano-rods of rutile phase and is an N-type semiconductor, and is quadrangular with a height of 500-4000 nm and a diameter of 40-250 nm, and orderly and vertically grown on the side walls of the silicon cones;
PPY is polypyrrole nano-particles with a diameter of 10-60 nm and is a P-type semiconductor, and is uniformly grown on the surfaces of the TiO2 nano-rods;
in the Si/TiO2/PPY three-dimensional bionic composite material, double P/N heterojunctions are formed on interfaces between Si and TiO2 and between TiO2 and PPY, such that the composite material can efficiently separate photo-generated charges while having a three-dimensional bionic composite structure, and can effectively reduce the reflection of incident light on the surface.
US Pat. No. 10,889,624

PROTEINS FROM THE WEBS OF NEPHILENGYS CRUENTATA, A VICULARIA JURUENSIS AND PARAWIXIA BISTRIATA SPIDERS ISOLATED FROM BRAZILIAN BIODIVERSITY

Empresa Brasileira de Pes...

1. A composition useful for modulating structural properties of material comprising: a host cell comprising at least one functionally expressed molecule of a spider nucleic acid operably linked to at least one regulatory element necessary for the expression of the molecule, wherein the spider nucleic acid encodes a protein from Nephilengys cruentata, and wherein the sequence of the molecule of spider nucleic acid is SEQ ID No. 1; and wherein the host cell is selected from the group consisting of bacterial cells, fungus cells, insect cells, mammal cells, and plant cells.
US Pat. No. 10,888,599

COMPOSITIONS AND METHODS TO IMPROVE EXERCISE PERFORMANCE AND RECOVERY

Beachbody, LLC, Santa Mo...

1. A method for improving exercise performance and/or recovery in a subject, or controlling body weight and/or promoting weight loss in the subject, comprising:administering an effective amount of a composition to the subject, thereby improving exercise performance and/or recovery in the subject,
wherein the composition comprises citric acid, beta alanine, quercetin, sodium citrate, stevia and/or stevia leaf extract, fruit flavor, green tea extract and/or natural caffeine, and potassium citrate.
US Pat. No. 10,889,625

PEPTIDE-BASED METHODS FOR TREATING NEUROLOGICAL INJURY

The Regents of the Univer...

1. An isolated peptide, wherein the isolated peptide is the amino acid sequence GSREPGEMLPRKLKRVLRQEFWV (SEQ ID NO:1), or KLKRVLRQEFWV (SEQ ID NO. 12).
US Pat. No. 10,888,600

METHODS AND AGENTS FOR TREATING ALZHEIMER'S DISEASE

THE GENERAL HOSPITAL CORP...

1. A method of treating a neuro-inflammation disorder associated with beta amyloid accumulation in a subject, the method comprising administering to a subject in need thereof an effective amount of an anti-CD33 antibody that binds to a cell-surface receptor encoded by CD33 and inhibits or reduces the expression or activity of CD33 protein.
US Pat. No. 10,889,626

COMBINED USE OF GDF TRAPS AND ERYTHROPOIETIN RECEPTOR ACTIVATORS TO INCREASE RED BLOOD CELL LEVELS

ACCELERON PHARMA INC., C...

1. A method for treating anemia associated with myelodysplastic syndrome in a subject in need thereof, wherein the subject is receiving or has received blood transfusions, wherein the method comprises administering to the subject an effective amount of a polypeptide comprising an amino acid sequence that is at least 90% identical to the sequence of amino acids 29-109 of SEQ ID NO: 1, wherein the polypeptide comprises an acidic amino acid at the position corresponding to position 79 of SEQ ID NO: 1, and wherein the polypeptide binds to GDF11 and/or myostatin.
US Pat. No. 10,888,088

CONCENTRATE COMPRISING A MEL AND A POLYETHYLENE GLYCOL FATTY ACID ESTER HAVING AN HLB VALUE GREATER THAN OR EQUAL TO 12

OLEON NV, Evergem (BE)

1. A concentrate comprising:at least one mannosylerythritol lipid (MEL), and
at least one polyethylene glycol fatty acid ester having an HLB value greater than or equal to 12,
in which the MELpolyethylene glycol fatty acid ester ratio is comprised between 0.1 and 2.
US Pat. No. 10,888,601

USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS

REGENERON PHARMACEUTICALS...

1. A method for treating age related macular degeneration in a patient in need thereof, comprising intravitreally administering, to said patient, an effective amount of aflibercept which is 2 mg approximately every 4 weeks for the first 3 months, followed by 2 mg approximately once every 8 weeks or once every 2 months.
US Pat. No. 10,889,627

PRO-DRUG PEPTIDE WITH IMPROVED PHARMACEUTICAL PROPERTIES

UREKA SARL, Mulhouse (FR...

1. A pro-drug peptide or salt thereof having improvement for at least one biological property relative to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism, the pro-drug peptide comprising the following structure:Zn-pep,
wherein:
pep is the parent peptide or peptidomimetic that is glucagon or an analog thereof; and
Z is attached to the n-terminus of pep and is cleaved in vivo releasing pep, wherein Z has the structure (Glu-Pro)X or (Lys-Pro)X, and X is an integer ?1.
US Pat. No. 10,888,089

METHODS AND COMPOSITIONS FOR CONTROLLING FUNGUS-GROWING ANTS

UNIVERSITE PARIS EST CRET...

1. A method for controlling fungus-growing ants, the method comprising administering on or around a nest of fungus-growing ants, near or on the fungus-growing ants, and/or in an area to be protected from fungus-growing ants a composition comprising at least one laccase inhibitor selected from the group consisting ofascorbic acid, citric acid, coumaric acid, ferulic acid, gallic acid, 6-1-palmitylascorbic acid, syringic acid, sodium ascorbate, calcium ascorbate, potassium ascorbate, butylhydroxyanisole, butylhydroxytoluol, cysteine, octyl gallate, dodecyl gallate, glutathione, sodium lactate, potassium lactate, calcium lactate, lecithins, lipoate, carotenoids, carotene, sodium tartrate, potassium tartrate, sodium thiosulfate, vitamin E, synthetic ?-tocopherol, synthetic ?-tocopherol, synthetic ?-tocopherol, selenium, hydroxylammonium chloride, ethylenediaminetetraacetic acid, calcium chloride, rhodotorulic acid, enterobactin, diethyldithiocarbamic acid, sodium azide, cetyltrimethylammonium bromide, sodium lauryl sulphate, sodium cyanide, sodium thiosulphate, oxalic acid, thioglycolic acid, diethyldithiocarbamic acid, Fe2+, Cu2+, Ag+, Li+, Sn+, Hg+, Mn2+, Zn2+, Al3+, thymol, and eugenol;
wherein the fungus-growing ants are killed and/or forced to abandon the nest after coming into contact with the at least one laccase inhibitor.
US Pat. No. 10,889,628

OPTOGENETIC INHIBITION OF OVERACTIVE NEURONAL ACTIVITY

Emory University, Atlant...

1. A recombinant protein comprising the amino acid sequence of SEQ ID NO: 11.
US Pat. No. 10,889,884

STEEL SHEET COATED WITH A METALLIC COATING BASED ON ALUMINUM

ArcelorMittal, Luxembour...

1. A steel sheet coated with a metallic coating, the metallic coating comprising:10 to 20% by weight of zinc;
7.1 to 12.0% by weight of silicon;
1.1 to 8.0% by weight of magnesium;
optionally additional elements chosen from Pb, Ni, Zr, or Hf, a content by weight of each additional element of the additional elements if present being less than 0.3% by weight; and
a balance being aluminum and unavoidable impurities and residuals elements, a weight ratio of Al/Zn being from 4.0 to 6.0; the coating not including Sn and not including In;
wherein a microstructure of the coating includes an Al—Zn phase, a Mg2Si phase, and a MgZn2 phase and wherein a thickness of the coating is between 10 and 35 ?m.
US Pat. No. 10,888,090

PLANT GROWTH PROMOTERS AND METHODS OF USING THEM

KING ABDULLAH UNIVERSITY ...

1. A method of promoting plant growth comprisingproviding a plant or plant part with a composition comprising an effective amount of a compound, wherein the compound is 3-OH-?-apo-13-carotenone, wherein the compound increases lateral root growth in Arabidopsis thaliana at a concentration between 0.1 ?M and 2.5 ?M.
US Pat. No. 10,888,603

METHODS OF TREATING CANCER CELLS EXPRESSING TUMOR-ASSOCIATED INTEGRINS

The Board of Trustees of ...

1. A method for treating a cancer comprising tumor cells expressing a tumor-associated integrin in a subject, comprising administering to the subject a therapeutically effective amount of:(a) interleukin (IL)-2;
(b) an integrin-binding-Fc fusion protein which binds to the tumor cells expressing the tumor-associated integrin; and
(c) a cancer vaccine,
wherein the integrin-binding-Fc fusion protein comprises (i) an integrin-binding polypeptide comprising an integrin-binding loop and a knottin polypeptide scaffold, and (ii) an immunoglobulin Fc domain, wherein the integrin-binding polypeptide is operably linked to the Fc domain.
US Pat. No. 10,889,629

TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of treating a patient who has cancer that presents a peptide consisting of the amino acid sequence of KVLEHVVRV (SEQ ID NO: 1) in a complex with HLA-A*02, comprising administering to the patient a population of transformed CD8+ T cells expressing at least one vector encoding a T cell receptor (TCR),wherein the TCR comprises SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 66, SEQ ID NO: 67, and SEQ ID NO: 68,
wherein the TCR is capable of binding to a peptide consisting of the amino acid sequence of KVLEHVVRV (SEQ ID NO: 1) in a complex with HLA-A*02, and
wherein the cancer is selected from non-small cell lung cancer (NSCLC), melanoma, and ovarian cancer (OC).
US Pat. No. 10,889,885

METHOD FOR SURFACE DECORATION OF ARTICLES

TAPEMATIC S.P.A., Ornago...

1. A method for surface decoration of articles, comprising the steps of:A) applying a base layer to a surface of a main body, the base layer comprising at least one photoluminescent additive suitable for conferring photoluminescence to the base layer;
B) after step A), applying on the base layer a metallization layer configured to make at least partially visible the photoluminescence of the base layer; step B) comprising depositing metal particles on the base layer;
C) after step B), applying a transparent coating layer on the base layer and metallization layer;
D) prior to step C) performing a material removal action removing a portion of the metal particles in accordance with a predetermined graphical pattern.
US Pat. No. 10,888,091

ADJUVANCY COMBINATION

Croda, Inc., Edison, NJ ...

1. An agrochemical formulation, comprising:i) a first adjuvant, where the first adjuvant is a fatty ester of an oligomer of glycerol having from 2 to 3 repeat units represented by formula (I):
P.[R1]m  (I)
wherein:
P is the residue of an oligomer of glycerol having from 2 to 3 repeat units and having m active hydrogen atoms;
m is an integer of 3 to 5;
each R1 is independently hydrogen, C8 to C12 alkyl, C16 to C20 alkenyl or an alkanoyl group represented by —C(O)R2, where at least one R1 is an alkanoyl group represented by —C(O)R2;
wherein the alkanoyl group represented by —C(O)R2 is a residue of a C16 to C22 fatty acid;
ii) a co-adjuvant, wherein the co-adjuvant is an alkoxylated alcohol represented by the formula (II):
R3—O-(AO)x—H  (II)
wherein
R3 is the residue of a fatty alcohol selected from capric alcohol, lauryl alcohol, myristyl alcohol;
each AO is, independently, an oxyethylene (EO) group or an oxypropylene (PO) group; and
x represents an integer in the range from 4 to 7; and
iii) at least one agrochemical active,
wherein:
the contact angle of the agrochemical formulation is less than 40°;
the surface tension of the agrochemical formulation is less than 32 mN/m; and
the viscosity range of the agrochemical formulation is 30 to 60 mPa·s.
US Pat. No. 10,888,604

POLYPEPTIDES AND ANALOGUES THEREOF FOR USE IN THE TREATMENT OF DIABETES AND BONE DISORDERS

1. A polypeptide comprising (i) the amino acid sequence HPXXPWIL (SEQ ID NO: 1), or an analogue thereof, wherein each X is independently selected from K, R, and Q and (ii) the amino acid sequence YAEGTFISDYSIAM (SEQ ID NO:6).
US Pat. No. 10,889,630

METHOD OF SEPARATING FACTOR VIII FROM BLOOD PRODUCTS

OCTAPHARMA AG, Lachen (C...

1. A method for separating a Factor VIII (FVIII) protein from a first composition comprising the FVIII protein, which contains at least the light chain of FVIII, and a von-Willebrand-Factor (vWF) protein which comprises at least the FVIII binding domain of vWF, wherein the FVIII protein can form a complex with the vWF protein, the method comprising the steps:contacting the first composition with an affinity resin comprising a ligand and a matrix, wherein the ligand has an affinity to the light chain of FVIII, and
separating the affinity resin from the mixture to obtain a modified first composition and a second composition, wherein the second composition contains the affinity resin and a complex of the FVIII protein and the vWF protein.
US Pat. No. 10,888,605

GLP-1 COMPOSITIONS AND USES THEREOF

1. A liquid pharmaceutical composition comprising semaglutide and phenol, wherein said composition(a) is for parenteral administration;
(b) is an aqueous solution comprising at least 60% w/w) water; or
(c) further comprises one or more pharmaceutically acceptable excipients selected from the group consisting of a buffer or an isotonic agent;
wherein the semaglutide is in the range of 0.5 mg/ml-5.0 mg/ml;
wherein the phenol is no more than 0.1 mg/ml; and
wherein the pH of the composition is in between 7.0 and 7.8.
US Pat. No. 10,889,631

THERAPEUTIC VARIANT ALPHA-2-MACROGLOBULIN COMPOSITIONS

Cytonics Corporation, Ju...

1. A method of treating a mammalian subject with an inflammatory disease or condition, comprising administering to the subject a pharmaceutical composition comprising(a) a pharmaceutically effective amount of a recombinant alpha-2-macroglobulin (A2M) polypeptide comprising a non-natural bait region, wherein the non-natural bait region comprises a sequence with at least 80% identity to SEQ ID NO: 20; and
(b) a pharmaceutically acceptable carrier.
US Pat. No. 10,888,093

USES OF THAXTOMIN AND THAXTOMIN COMPOSITIONS AS HERBICIDES

MARRONE BIO INNOVATIONS, ...

1. A synergistic herbicidal composition for controlling dandelion and/or plantain comprising 0.1 to 0.24 mg/ml of thaxtomin A and 0.176 to 2.34 mg/ml of 2,4-Dichlorophenoxyacetic acid (2,4-D), wherein thaxtomin A and 2,4-D are present in a synergistic amount to control dandelion and/or plantain.
US Pat. No. 10,888,606

ANTI-INFLAMMATORY PEPTIDES AND COMPOSITIONS COMPRISING THE SAME

1. An anti-inflammatory composition comprising an isolated peptide 5 amino acids in length consisting of the amino acid sequence of SEQ ID NO: 101 as an active ingredient.
US Pat. No. 10,889,632

HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF

Institute for Research in...

1. A vector comprising one or more nucleic acid molecules encoding a heavy chain variable region and/or light chain variable region of an antibody that binds to hCMV, wherein the heavy chain variable region is encoded by the nucleotide sequence SEQ ID NO: 63, and the light chain variable region is encoded by the nucleotide sequence SEQ ID NO: 64.
US Pat. No. 10,888,607

MARKER FOR ACID SPHINGOMYELINASE DISORDERS AND USES THEREOF

Genzyme Corporation, Cam...

1. A method of treating an acid sphingomyelinase (ASM) deficiency in a human subject, wherein the method comprises:(a) administering to the subject a therapeutic agent for the ASM deficiency; and
(b) obtaining the level of lyso-sphingomyelin (lyso-SPM) in a biological sample from the subject collected three or more days after step (a), wherein the biological sample is a blood sample and a decrease of the level of lyso-SPM compared to a reference level indicates efficacy of the therapeutic agent.
US Pat. No. 10,889,633

HUMAN IMMUNODEFICIENCY VIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF

The Rockefeller Universit...

1. A therapeutic composition comprising:i. a recombinantly produced monoclonal anti-HIV antibody or an HIV gp120-derived antigen-binding fragment thereof comprising the CDR1, CDR2, and CDR3 regions of the sequence of SEQ ID NO: 896 and the CDR1, CDR2, and CDR3 regions of SEQ ID NO: 910 and
ii. a pharmaceutically acceptable carrier.
US Pat. No. 10,889,889

HIGH PURITY COPPER SPUTTERING TARGET MATERIAL

MITSUBISHI MATERIALS CORP...

1. A high purity copper sputtering target material comprising Cu at a purity of 99.99998 mass % or more excluding O, H, N and C, whereinan Al content is 0.005 mass ppm or less,
a Si content is 0.05 mass ppm or less,
an Fe content is 0.02 mass ppm or less,
a S content is 0.03 mass ppm or less,
a Cl content is 0.1 mass ppm or less,
an O content is 1 mass ppm or less,
a H content is 1 mass ppm or less,
a N content is 1 mass ppm or less,
a C content is 1 mass ppm or less, and
a value of L15°/L is 0.8 or more, L being a total length of grain boundaries formed between adjacent crystal grains with a crystal orientation difference in a range of more than 2° and 180° or less, and L15° being a length of large tilt angle grain boundaries formed between adjacent crystal grains with a crystal orientation difference in a range of 15° or more and 180° or less.
US Pat. No. 10,888,095

STABLE HERBICIDAL COMPOSITIONS

UPL LIMITED, Haldia (IN)...

1. A stable herbicidal composition comprising:(i) glufosinate ammonium salt as an active ingredient in an amount of about 5% to about 50% by weight of the composition;
(ii) at least one (C8-C20)alkyl-dimethylamine N-oxide in an amount of about 8% to about 35 wt % by weight of the composition, wherein the at least one (C8-C20)alkyl-dimethylamine N-oxide is selected from the group consisting of decyldimethylamine N-oxide, dodecyldimethylamine N-oxide, and tetradecyldimethylamine N-oxide;
(iii) ammonium sulfate in an amount of about 1% to about 10% by weight of the composition; and
(iv) an organic solvent comprising a glycol and an alkoxy aliphatic alcohol, in an amount of about 1% to about 40% by weight of the composition;
wherein the composition remains clear at a temperature of ?5° C. for at least 14 days.
US Pat. No. 10,888,608

COSTIMULATION OF CHIMERIC ANTIGEN RECEPTORS BY MYD88 AND CD40 POLYPEPTIDES

Bellicum Pharmaceuticals,...

1. A nucleic acid comprising a polynucleotide, in order from 5? to 3?, encoding(a) a chimeric antigen receptor, comprising, in order from the amino terminus of the receptor, (i) an scFv antigen recognition moiety; (ii) a transmembrane region; and (iii) a CD3 zeta polypeptide;
(b) linker polypeptide, wherein the linker polypeptide is a cleavable 2A polypeptide that links the chimeric antigen receptor to the chimeric stimulating molecule; and
(c) a chimeric stimulating molecule, wherein:
the chimeric stimulating molecule comprises (i) a truncated MyD88 polypeptide lacking the TIR domain, and (ii) a CD40 cytoplasmic polypeptide region lacking the CD40 extracellular domain;
the chimeric stimulating molecule is constitutively active;
the chimeric stimulating molecule does not include a dimerization or multimerization molecule binding region; and
the polynucleotide is operably linked to a promoter.
US Pat. No. 10,889,634

ANTI-AGE ANTIBODIES AND METHODS OF USE THEREOF

Siwa Corporation, Chicag...

1. An anti-AGE antibody, comprisinga heavy chain, and
a light chain,
wherein the heavy chain comprises an amino acid sequence having at least 90% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NO: 29, SEQ ID NO: 31, and SEQ ID NO: 33,
the light chain comprises an amino acid sequence having at least 90% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NO: 35, SEQ ID NO: 37, and SEQ ID NO: 39, and
the antibody binds to a protein or peptide that exhibits a carboxymethyllysine modification.
US Pat. No. 10,888,096

BIOPESTICIDES FOR POTATO LATE BLIGHT DISEASE

Her Majesty the Queen in ...

1. A method of controlling or treating potato late blight disease in plants, the method comprising:formulating a bacterial culture into a biopesticidal formulation; and
applying an effective amount of the biopesticidal formulation to a plant, or part thereof, infected by, or at risk of infection by, Phytophthora infestans;
wherein the bacterial culture comprises an effective amount of one or more bacteria selected from the group consisting of:
Pseudomonas chlororaphis strain 189, International Depositary Authority of Canada accession number 151116-02;
Bacillus subtilis strain WAUSV36, International Depositary Authority of Canada accession number 151116-01;
Pseudomonas fluorescens strain UWO1, International Depositary Authority of Canada accession number 151116-03;
Pseudomonas fluorescens strain KENGFT3, International Depositary Authority of Canada accession number 151116-05;
Arthrobacter sp. strain OY3WO11, International Depositary Authority of Canada accession number 151116-04; and
Pantoea sp. strain OXWO6B1, International Depositary Authority of Canada accession number 151116-06.
US Pat. No. 10,888,609

CD200 INHIBITORS AND METHODS OF USE THEREOF

Regents of the University...

1. A composition comprising a CD200 inhibitor, wherein the CD200 inhibitor is a mutant of naturally-occurring CD200 peptide, wherein the CD200 inhibitor is 13 to 20 amino acids in length, and wherein the peptide comprises the amino acid sequence VTWQKKAAVSPEN (SEQ ID NO: 21).
US Pat. No. 10,889,635

AGENTS, USES AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHY

1. A method of treating Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson's disease, and multiple system atrophy in a subject, said method comprising administering(I) a monoclonal antibody or antigen-binding fragment thereof comprising:
(i) a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:1;
(ii) a Heavy Chain CDR2 having the amino acid sequence selected from SEQ ID NO:2, SEQ ID NO:33, SEQ ID NO:34, or SEQ ID NO:35;
(iii) a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:3;
(iv) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:4;
(v) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:5; and
(vi) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:6; or
(II) a monoclonal antibody or antigen-binding fragment thereof comprising:
(i) a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:20;
(ii) a Heavy Chain CDR2 having the amino acid sequence of SEQ ID NO:21;
(iii) a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:22;
(iv) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:23;
(v) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:24; and
(vi) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:25; andan additional medicament selected from the group comprising pramipexole, VX-765, ABT-957, PF-06447475, NB-360, Neuropore NPT100-18A, NPT200-11, EGCG, Bapineuzemab, Solanezumab, Gantenerumab, Crenezumab, Aducanumab, C16H15NO4, BMS-986016, GSK2831781, IMP321, ELN484228, NCGC607, Miglustat, Eliglustat, Rasagiline, Selegiline, Ropinirole, Bromocriptine, Entacapone, Tolcapone and Istradefyline.
US Pat. No. 10,888,610

IMMUNOGENIC COMPLEX FOR ELICITING PROTECTIVE IMMUNITY AGAINST GROUP B STREPTOCOCCUS

MINERV AX APS

1. An immunogenic complex comprising:an amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a group B Streptococcus surface protein, and
a capsular polysaccharide,
wherein the immunogenic complex is capable of eliciting protective immunity against group B Streptococcus,
wherein the amino acid sequence is conjugated to the capsular polysaccharide, and
wherein the group B Streptococcus surface protein is selected from the group consisting of Rib protein, Alp2 protein, Alp3 protein, Alp4 protein, and AlpC protein, and
wherein the amino acid sequence has at least 80% sequence identity with one of the amino acid sequences SEQ ID Nos 2, 4, 10 and 14, and
wherein there is only one amino acid sequence, having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a group B Streptococcus surface protein, in the immunogenic complex.
US Pat. No. 10,889,636

ANTI-LAMININ4 ANTIBODIES SPECIFIC FOR LG4-5

PROTHENA BIOSCIENCES LIMI...

1. A method of treating a patient having a cancer, the method comprising administering to the patient an effective regime of an antibody that specifically binds to an epitope within the LG4-5 modules of the G domain of laminin ?4, wherein the antibody comprises three light chain CDRs and three heavy chain CDRs from the heavy and light chain variable regions of SEQ ID NOS:16 and 17, respectively, SEQ ID NOS:26 and 27, respectively, or SEQ ID NOS:36 or 37, and 38, respectively.
US Pat. No. 10,888,611

NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS THEREOF

PFIZER INC., New York, N...

1. A method of inducing bactericidal immune response against a Neisseria meningitidis serogroup B subfamily A strain and against a Neisseria meningitidis serogroup B subfamily B strain in a human comprising concomitantly administering an effective amount of a N. meningitidis rLP2086 composition and three additional immunogenic compositions, wherein said N. meningitidis rLP2086 composition comprises (a) a first lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 1 and (b) a second lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2, wherein the N. meningitidis rLP2086 composition comprises about 2.8 molar ratio of polysorbate-80, wherein the three additional immunogenic compositions comprise (i) an immunogenic composition comprising four distinct and separately made carrier protein-capsular polysaccharide conjugates against Neisseria meningitidis serogroup A, Neisseria meningitidis serogroup C, Neisseria meningitidis serogroup Y, and Neisseria meningitidis serogroup W135; (ii) an immunogenic composition against diphtheria, tetanus, and pertussis comprising diphtheria toxoid, tetanus toxoid, and acellular pertussis antigens; and (iii) an immunogenic composition against human papillomavirus (HPV).
US Pat. No. 10,889,637

METHODS OF TREATING AN OSTEOLYTIC TUMOR AND SPINAL CORD INJURY BY ADMINISTERING CONNEXIN (CX) 43 HEMICHANNEL-BINDING ANTIBODIES

THE BOARD OF REGENTS OF T...

1. A method of treating an osteolytic tumor in a subject, the method comprising administering to the subject an effective amount of an antibody that binds to a connexin 43 (Cx43) hemichannel and enhances channel opening, wherein the antibody comprises:(a) a first VH CDR identical to SEQ ID NO: 19;
(b) a second VH CDR identical to SEQ ID NO: 20;
(c) a third VH CDR identical to SEQ ID NO: 21;
(d) a first VL CDR identical to SEQ ID NO: 49;
(e) a second VL CDR identical to SEQ ID NO: 50; and
(f) a third VL CDR identical to SEQ ID NO: 51.
US Pat. No. 10,888,612

DNA VACCINE AGAINST VIRUS OF YELLOW FEVER

The Johns Hopkins Univers...

1. An antigen comprising the amino acid sequence encoded by SEQ ID NO: 11, wherein the amino acid sequence is Yellow Fever Virus PreM/M-E protein fused to LAMP.
US Pat. No. 10,888,100

DAIRY PRODUCT AND PROCESS

Fonterra Co-Operative Gro...

1. A method for preparing a mixture comprising a liquid whey protein concentrate (WPC) or whey protein isolate (WPI), comprising:(a) providing an aqueous WPC or WPI solution having a protein concentration of 15-50% (w/v), at a pH of between 5.5 and 8.5;
(b) pressurizing the provided aqueous solution into a flow path;
(c) heat treating the pressurized solution to more than 50° C. and not more than 150° C., for a time that allows protein denaturation to occur, wherein at least 50% of denaturable proteins are denatured, said time being less than about 120 s; the heat treating comprising heating the solution while under conditions of turbulent flow with a Reynold's number of at least 500 and wherein the volume weighted mean particle size D[4,3] of the whey protein particles in the pressurized solution is less than about 10 ?m and the pressurized solution is not subjected to a mechanical shear process to break up particles within the solution; and
(d) at the end of the heat treatment, either
(i) transferring the heat treated material directly to a mixer to be mixed with at least one other ingredients, including at least one of the group consisting of milk, skim milk, fat, a carbohydrate, milk retentate, or skim milk retentate, or
(ii) transferring the heat treated material promptly to a drier and drying the heat treated WPC or WPI;
wherein the heat-treated WPC or WPI is not subjected to a mechanical shear process to break up particles within the solution prior to either the optional drying step or the optional mixing step other than a mechanical shear wherein liquid is converted into droplets to facilitate drying.
US Pat. No. 10,888,613

METHOD OF PRODUCING CELLS RESISTANT TO HIV INFECTION

American Gene Technologie...

1. A method of producing cells that are resistant to HIV infection, the method comprising:(a) contacting peripheral blood mononuclear cells (PBMC) isolated from a subject that is HIV-negative with a therapeutically effective amount of a stimulatory agent, wherein the contacting is carried out ex vivo;
(b) transducing the PBMC ex vivo with a viral delivery system encoding at least one genetic element, wherein the at least one genetic element comprises a microRNA capable of at least one of inhibiting production of chemokine receptor CCR5 or targeting an HIV RNA sequence,
wherein the microRNA comprises a sequence having at least about 90% identity with SEQ ID NO: 31; and
(c) culturing the transduced PBMC for at least 1 day.
US Pat. No. 10,892,457

METHOD OF PRODUCING LAMINATED SEPARATOR FOR NONAQUEOUS ELECTROLYTE SECONDARY BATTERY

SUMITOMO CHEMICAL COMPANY...

1. A method of producing a laminated separator for a nonaqueous electrolyte secondary battery, the laminated separator including (i) a porous film containing a polyolefin-based resin at a proportion of not less than 50% by volume and (ii) a porous layer containing a polyvinylidene fluoride-based resin, the method comprising the steps of:(1) applying a coating solution, in which the polyvinylidene fluoride-based resin is dissolved, to the porous film to form a coating layer;
(2) separating the polyvinylidene fluoride-based resin out of the coating layer; and
(3) adjusting a gloss of the coating layer from which the polyvinylidene fluoride-based resin has been separated,
wherein the gloss is adjusted by a chemical treatment, a physical treatment of removing a surface of the coating layer, a corona treatment, or a plasma treatment.
US Pat. No. 10,888,101

CONFECTIONERY COMPOSITION AND A METHOD OF MANUFACTURING THEREOF

1. A method of manufacturing a confectionery composition, comprising steps of:preparing an alcohol-containing phase comprising about 36% to about 60% alcohol by volume at a first temperature from about 30° C. to about 60° C.;
preparing a sweet-containing phase at a second temperature where the second temperature is higher than the first temperature, the second temperature being from about 120° C. to about 140° C.;
incorporating a minority portion of the alcohol-containing phase into the sweet-containing phase followed by mixing and intermediate setting to form a mixture having a lower temperature than the second temperature of the sweet-containing phase;
incorporating a further minority portion of the alcohol-containing phase into the lower temperature mixture followed by mixing and intermediate setting;
repeating the step of incorporating a further minority portion of the alcohol-containing phase into the lower temperature mixture followed by mixing and intermediate setting until a third temperature of said lower temperature mixture ranges from about 60° C. to about 65° C. and then fully incorporating a remaining portion of the alcohol-containing phase into the lower temperature mixture;
allowing the resultant mixture to set to form the composition;
wherein, when set, the composition is in the form of a single-phase amorphous mass.
US Pat. No. 10,888,614

EMULSIONS FOR INJECTABLE FORMULATIONS

Croda International Plc

1. A vaccine formulation comprising a water-in-oil emulsion and at least one vaccine antigen, oil, and water, where said emulsion comprises an emulsifier having a general structure (I):R1.[(AO)n—R2]m  (I)
wherein
R1 is the residue of a polyol or polyamine, each said polyol or polyamine having m active hydrogen atoms, where m is an integer of at least 2;
AO is an oxyalkylene group;
each n independently represents an integer in the range from 1 to 100;
each R2 independently represents hydrogen, or an acyl group represented by —C(O)R3 wherein each R3 independently represents a residue of Polyhydroxyalkyl carboxylic acid, polyhydroxyalkenyl carboxylic acid, hydroxyalkyl carboxylic acid, hydroxyalkenyl carboxylic acid, oligomer of hydroxyalkyl carboxylic acid, or oligomer of hydroxyalkenyl carboxylic acid; and
wherein on average at least two R2 groups per molecule are alkanoyl groups as defined.
US Pat. No. 10,888,615

NEUTRALIZING HUMAN MONOCLONAL ANTIBODY 8D6 AGAINST HCV INFECTION

SUZHOU GALAXY BIOPHARMA, ...

1. An isolated binding molecule, wherein the binding molecule comprises CDR1 heavy chain set forth in SEQ ID NO: 8, CDR2 heavy chain set forth in SEQ ID NO: 9, CDR3 heavy chain set forth in SEQ ID NO: 10, CDR1 light chain set forth in SEQ ID NO: 14, CDR2 light chain set forth in SEQ ID NO: 15, and CDR3 light chain set forth in SEQ ID NO: 16; wherein said isolated binding molecule is an antibody; and wherein said binding molecule specifically binds to hepatitis C virus E2 protein.
US Pat. No. 10,889,641

ANTI-GM-CSF ANTIBODIES AND USES THEREOF

I-Mab Biopharma Co., Ltd....

1. An antibody or antigen-binding fragment thereof, wherein the antibody or fragment thereof has specificity to a human granulocyte macrophage colony-stimulating factor (GM-CSF) protein and comprises a heavy chain variable region (VH) complementarity determining region (CDR) 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 23, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 24, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 25, a light chain variable region (VL) CDR1 comprising the amino acid sequence of SEQ ID NO: 26, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 27, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 28.
US Pat. No. 10,888,616

STABILIZED GLUCAGON SOLUTIONS

LATITUDE PHARMACEUTICALS,...

1. A ready-to-use, non-gelling, clear and one-phase solution composition, the composition comprising: glucagon having a concentration between 0.05 mg/mL and 5 mg/mL, water having a concentration between 3% and 5% w/v, an anti-gelling polyol comprising a combination of a propylene glycol and polyethylene glycol having a concentration between 60% and 97% w/v, an acid in sufficient quantity to adjust pH of the composition to a pH between 2 and 4, a stabilizing-salt selected from the group consisting of sodium chloride, calcium chloride, sodium acetate or a combination thereof, having a concentration between 0.5% and 3% w/v, an antioxidant selected from the group consisting of methionine, EDTA or a combination thereof having a concentration between 0.01% and 1% w/v, and optionally ethanol as a viscosity-reducer, wherein the clear and one-phase composition is free from cationic surfactants or a phospholipid and retains no less than 65% of the initial glucagon concentration after 24-month storage at 2-8° C.
US Pat. No. 10,889,642

TREATMENT OF FIBROSIS WITH INTERLEUKIN-11 RECEPTOR ALPHA ANTIBODY

Singapore Health Services...

1. A method of treating a disease or condition characterised by fibrosis of the eye in a human subject, the method comprising administering to the human subject in need of treatment a therapeutically effective amount of an Interleukin 11 receptor ? (IL-11R?) antibody which is capable of inhibiting Interleukin 11 (IL-11) mediated signaling.
US Pat. No. 10,888,104

FATTY ACID COMPOSITION AND METHOD FOR FORTIFYING NUTRITIONAL PRODUCTS WITH FATTY ACIDS

Jost Chemical Co., St. L...

1. A fatty acid composition for making fatty acid fortified nutritional products; the fatty acid composition being in powder form; the fatty acid composition comprising: a fatty acid component including a desired fatty acid chosen from the group consisting of arachidonic acid (ARA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), eicosatetraenoic acid, heneicosapentaenoic acid, docosahexaenoic acid (DHA), and combinations thereof, optionally at least one vitamin, a salt that is not a fatty acid salt, an optional protein source, and an optional carbohydrate source; wherein the fatty acid component consists of a monovalent simple fatty acid salt, wherein the desired fatty acid comprises at least 24 wt % of the fatty acid composition, wherein the fatty acid composition is not microencapsulated; and wherein the fatty acid composition is substantially instantizable in liquid upon stirring, shaking, or otherwise agitating in any effective manner the fatty acid composition powder in the liquid for less than one minute.
US Pat. No. 10,888,617

CURED OIL-HYDROGEL BIOMATERIAL COMPOSITIONS FOR CONTROLLED DRUG DELIVERY

ATRIUM MEDICAL CORPORATIO...

1. A method of modulating the rate of release of one or more therapeutic agents from a coating material, the method comprising the steps of:providing a biomaterial, wherein the biomaterial comprises fatty acids cross-linked to each other;
coupling a fixating material to the biomaterial to form the coating material, wherein the fixating material comprises material selected from the group consisting of sodium carboxymethylcellulose (Na-CMC), poly(ethylene oxide), poly(HEMA), poly(N-vinyl pyrrolidone), poly(acrylic acid), carboxymethyl cellulose (CMC), and chitosan, and wherein the fixating material is coupled to the biomaterial as a fixating material layer disposed on an outer surface of the biomaterial layer so that the biomaterial protonates the fixating material so as to alter a drug eluting property of the fixating material, and wherein at least the fixating material comprises one or more therapeutic agents; and
delivering, in a controlled manner, the one or more therapeutic agents in a patient from the coating material, wherein the rate of release of the one or more therapeutic agents from the coating material is based on at least the altered drug eluting property of the fixating material.
US Pat. No. 10,889,643

IMMUNE-STIMULATING HUMANIZED MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2, AND FUSION PROTEINS THEREOF

1. An isolated antibody, or antigen-binding portion thereof, which binds human interleukin-2 (IL-2) according to SEQ ID NO: 109, wherein said antibody or antigen-binding portion thereof comprises a light chain variable region comprising LCDR1, a LCDR2 and a LCDR3 and a heavy chain variable region comprising a HCDR1, a HCDR2 and a HCDR3 and wherein the LCDR1 comprises SEQ ID NO: 122; wherein LCDR2 comprises SEQ ID NO: 123; wherein LCDR3 comprises SEQ ID NO: 21; wherein HCDR1 comprises SEQ ID NO: 119; wherein HCDR2 comprises SEQ ID NO: 120; and wherein HCDR3 comprises SEQ ID NO: 121.
US Pat. No. 10,892,461

BUSBAR WITH INSULATION COATING FOR NEW ENERGY AUTOMOBILE

SHANGHAI VEKAN PRECISION ...

1. A busbar comprising:a busbar body and an insulating layer sprayed on the busbar body, wherein a raw material formula of the insulating layer comprises following materials in mass percent:
high aluminum cement of 3˜12%; attapulgite clay of 3˜9%; porcelain clay of 3˜9%; titanium dioxide of 2˜5%; multi-walled carbon nanotubes of 2˜6%; boron phosphate of 2˜6%; n-methylol acrylamide of 2˜5%; aluminum dihydrogen phosphate 3˜9%; tri-block copolymer styrene-butzdiene-methyl methacrylate of 3˜7%; methylphenyl silicone resin of 3˜7%; vinyl silicone oil 3˜7%; polyvinyl acetate emulsion 10˜19%; deionized water for balance.
US Pat. No. 10,888,618

METHOD OF TREATING CANCER

Intensity Therapeutics, I...

1. A method of treating cancer in a subject in need thereof comprising intratumorally administering a pharmaceutical composition comprising an aqueous solution, the aqueous solution comprising a therapeutically effective amount of a therapeutic agent and an intracellular permeation enhancing agent, wherein the therapeutic agent is a chemotherapeutic agent, an interfering RNA, a therapeutic protein or a therapeutic antibody, wherein the therapeutic agent is mixed with and not covalently bound to the intracellular permeation enhancing agent, and wherein the intracellular permeation enhancing agent is 6-Oxo-6-phenylhexanoic acid, 8-Oxo-8-phenyloctanoic acid, 8-(2,5-Dichlorophenyl)-8-oxooctanoic acid, N-[8-(2-hydroxybenzoyl)aminooctanoic acid, N-[8-(2-hydroxybenzoyl)aminodecanoic acid, N-(5-chlorosalicyloyl)-8-aminocaprylic acid, N-[4-(4-chloro-2hydroxybenzoyl)amino1 butanoic acid, 2-ethylhexyl 2-hydroxybenzoate, 5-Cyclohexyl-5-oxovaleric acid, 6-Cyclohexyl-6-oxohexanoic acid, 7-Cyclohexyl-7-oxoheptanoic acid, 8-Cyclohexyl-8-oxooctanoic acid, 4-Cyclopentyl-4-oxobutyric acid, 5-Cyclopentyl-5-oxovaleric acid, 6-Cyclopentyl-6-oxohexanoic acid, 7-Cyclopentyl-7-oxoheptanoic acid, 8-Cyclopentyl-8-oxooctanoic acid, 4-Cyclobutyl-4-oxobutyric acid, 5-Cyclobutyl-5-oxovaleric acid, 6-Cyclobutyl-6-oxohexanoic acid, 7-Cyclobutyl-7-oxoheptanoic acid, 8-Cyclobutyl-8-oxooctanoic acid, 4-Cyclopropyl-4-oxobutyric acid, 5-Cyclopropyl-5-oxovaleric acid, 6-Cyclopropyl-6-oxohexanoic acid, 7-Cyclopropyl-7-oxoheptanoic acid, 8-Cyclopropyl-8-oxooctanoic acid, a functionally effective salt of any of the foregoing, or any combination thereof.
US Pat. No. 10,889,644

HUMANIZED ANTI-BAG3 ANTIBODIES

BIOUNIVERSA S.R.L., Mont...

1. A humanized antibody or a fragment thereof that binds to BAG3 protein and comprises:a) a heavy chain comprising the following CDRs: H-CDR1 comprising the amino acids GFNIKDTYMY (SEQ ID NO: 3), H-CDR2 comprising the amino acids GVDPANGNTRYDPKFQG (SEQ ID NO: 4), H-CDR3 comprising the amino acids DGAMDY (SEQ ID NO: 5), and
b) a light chain comprising the following CDRs: L-CDR1 comprising the amino acids KSSQSLLYSSNQKNYLA (SEQ ID NO: 6), L-CDR2 comprising the amino acids WASTRES (SEQ ID NO: 7) and L-CDR3 comprising the amino acids QQYYTYPLT (SEQ ID NO: 8).
US Pat. No. 10,888,619

STABLE AQUEOUS ETANERCEPT COMPOSITION

Coherus BioSciences, Inc....

1. A stable aqueous pharmaceutical composition comprisingan aqueous carrier;
about 50 mg/mL etanercept, about 1% (w/v) sucrose, 0.26% (w/v) to 2% (w/v) mannitol or lysine; the aqueous carrier comprises a buffer, the composition is free of arginine and cysteine, the composition has a pH of about 6.0 to about 6.6, the composition has at least 90 wt. % correctly folded etanercept, the composition has less than 1 wt. % aggregates of etanercept, and
has at M3 or T2 or T4 no more than, on average, about 10,000 subvisible particles per mL having a size greater than 5 ?m, and
wherein said composition contains less than 50 mM NaCl, and the combination of said sucrose and said mannitol or lysine stabilizes said etanercept in said stable aqueous pharmaceutical composition, wherein the composition has an osmolality from about 180 to about 420 mOsM, and wherein the etanercept is prepared by a mixed mode cation exchange chromatography and mixed mode anion exchange chromatography method resulting in less than 1 wt. % aggregates of etanercept.
US Pat. No. 10,889,645

ENGINEERED T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME

IMMATICS BIOTECHNOLOGIES ...

1. A method of treating a patient who has cancer that presents a peptide consisting of the amino acid sequence of FLLDGSANV (SEQ ID NO: 1) in a complex with HLA-A*02, comprising administering to the patient a population of transformed T cells expressing at least one vector encoding a T cell receptor (TCR),wherein the TCR comprises SEQ ID NOs: 26, 6, 7, 40, 14, and 15,
wherein the TCR binds to a peptide consisting of the amino acid sequence of FLLDGSANV (SEQ ID NO: 1) in a complex with HLA-A*02, and
wherein the cancer is selected from breast cancer, gallbladder cancer, colon cancer, esophageal cancer, gastrointestinal carcinoid tumor, lung cancer, melanoma, non-Hodgkin lymphoma, pancreatic cancer, rectal cancer, gastric cancer, and urinary bladder cancer.
US Pat. No. 10,888,620

LIQUID COMPOSITIONS FOR TREATING COUGH OR COLD SYMPTOMS

1. A liquid composition for treating cough or cold symptoms, wherein said liquid composition comprises between about 0.1% and 3.0% of a mucoadhesive material, wherein said mucoadhesive material is a hydroxypropylmethylcellulose, and wherein said liquid composition further comprising from about 0.1% and 1.5% surfactant and wherein said surfactant comprises poloxamer 188, wherein said liquid composition has a traction coefficient of less than about 0.01 at 1-15 mm/sec rolling speed at 37° C., a slide to roll ratio (SRR) of 50% and 2 N normal load.
US Pat. No. 10,889,646

USE OF KIT INHIBITORS TO CONDITION SUBJECTS FOR A HEMATOPOIETIC STEM CELL (HSC) TRANSPLANTATION

1. A method of conditioning a subject for a hematopoietic stem cell (HSC) transplantation, the method comprising:administering an effective amount of an inhibitor of a stem cell growth factor receptor (KIT) to a subject who is in need of a HSC transplantation, wherein the subject is hypersensitive to at least one DNA damaging agent;
wherein the subject is free of irradiation treatment or a conditioning regimen comprising a DNA damaging agent before the transplantation of the HSCs.
US Pat. No. 10,889,902

DETERGENT COMPOSITION AND AEROSOL COMPOSITION OF SAME

KOBEGOSEI CO., LTD., Ono...

1. A detergent composition for washing automobiles, two-wheeled vehicles, bicycles, construction equipment, farm equipment, aircraft, railroad cars, ships, and/or various other types of car/vehicle/transportation means comprising: (Z)-1-chloro-3,3,3-trifluoropropene and HFE-type nonflammable fluorinated-type solvent, mass % ratio thereof ((Z)-1-chloro-3,3,3-trifluoropropene/HFE-type nonflammable fluorinated-type solvent) being within a range that is 30/70 to 99/1.
US Pat. No. 10,888,621

INJECTABLE TISSUE ADHESIVE HYDROGEL INCLUDING GAMMA-CYCLODEXTRIN AND BIOMEDICAL USE THEREOF

INCHEON UNIVERSITY INDUST...

1. A method of making an injectable tissue-adhesive hydrogel composition in situ comprising gamma-cyclodextrin (?-CD),wherein the injectable tissue adhesive hydrogel composition is cross-linked in situ by adding horseradish peroxidase and hydrogen peroxide to a mixture comprising at least one ?-CD, which is substituted or unsubstituted with a thiol group, and at least one homogeneous or heterogeneous polymer with a main chain in which phenol or 4-aminophenol and at least one functional group selected from an amino group and a carboxyl group are contained,
wherein the hydrogel is bonded by host-guest interaction between the at least one homogeneous or heterogeneous polymer and the ?-CD, the hydrogel is cross-linked in situ by phenol-phenol bonding between phenols or 4-aminophenols contained in a side branch of the main chain, and the hydrogel is cross-linked in situ by hydrogen bonding between a hydroxyl group of the ?-CD and the at least one functional group selected from the amino group and the carboxyl group, and
wherein the homogeneous or heterogeneous polymer is 3-(4-hydroxyphenyl)propionic acid-conjugated gelatin (GH) polymer, and the host-quest interaction between the ?-CD and the polymer is at a ratio of 1:2.
US Pat. No. 10,889,647

HUMANIZED, MOUSE OR CHIMERIC ANTI-CD47 MONOCLONAL ANTIBODIES

Forty Seven, Inc., Foste...

1. An antibody that binds human CD47, comprising:a) a VH-CDR1 sequence comprising the sequence set forth in SEQ ID NO:49, a VH-CDR2 sequence comprising the sequence set forth in SEQ ID NO:50, a VH-CDR3 sequence comprising the sequence set forth in SEQ ID NO:51, a VL-CDR1 sequence comprising the sequence set forth in SEQ ID NO:55, a VL-CDR2 sequence comprising the sequence set forth in SEQ ID NO:152, and a VL-CDR3 sequence comprising the sequence set forth in SEQ ID NO:57, wherein the CDR amino acids are according to Kabat; or
b) a VH-CDR1 sequence comprising the sequence set forth in SEQ ID NO:52, a VH-CDR2 sequence comprising the sequence set forth in SEQ ID NO:53, a VH-CDR3 sequence comprising the sequence set forth in SEQ ID NO:54, a VL-CDR1 sequence comprising the sequence set forth in SEQ ID NO:58, a VL-CDR2 sequence comprising the sequence set forth in SEQ ID NO:153, and a VL-CDR3 sequence comprising the sequence set forth in SEQ ID NO:60, wherein the CDR amino acids are according to IMGT;
c) a VH-CDR1 sequence comprising the sequence set forth in SEQ ID NO:49, a VH-CDR2 sequence comprising the sequence set forth in SEQ ID NO:50, a VH-CDR3 sequence comprising the sequence set forth in SEQ ID NO:51, a VL-CDR1 sequence comprising the sequence set forth in SEQ ID NO:55, a VL-CDR2 sequence comprising the sequence set forth in SEQ ID NO:56, and a VL-CDR3 sequence comprising the sequence set forth in SEQ ID NO:57, wherein the CDR amino acids are according to Kabat; or
d) a VH-CDR1 sequence comprising the sequence set forth in SEQ ID NO:52, a VH-CDR2 sequence comprising the sequence set forth in SEQ ID NO:53, a VH-CDR3 sequence comprising the sequence set forth in SEQ ID NO:54, a VL-CDR1 sequence comprising the sequence set forth in SEQ ID NO:58, a VL-CDR2 sequence comprising the sequence set forth in SEQ ID NO:59, and a VL-CDR3 sequence comprising the sequence set forth in SEQ ID NO:60, wherein the CDR amino acids are according to IMGT.
US Pat. No. 10,888,109

NITRITE-DEGRADING AND TSNA-DEGRADING BACTERIA AND METHODS OF MAKING AND USING

Altria Client Services LL...

1. A method of reducing the amount of at least one tobacco-specific nitrosamine (TSNA) in a composition comprising tobacco, comprising contacting said composition with an isolated bacterial strain of Myroides odoratus comprising a 16S rDNA sequence at least 98% identical to SEQ ID NO: 1 under conditions in which the amount of said at least one TSNA is reduced in said composition, wherein said conditions comprise (a) a moisture content from about 45% to about 75% by weight of said tobacco; (b) a temperature from about 20° C. to about 45° C.; (c) a pH of about 5 to about 8; or (d) any combination of (a), (b), and (c), thereby producing a reduced-TSNA composition.
US Pat. No. 10,889,648

ANTI-PD-L1 ANTIBODIES AND USES THEREOF

JIANGSU HYAMAB PHARMACEUT...

1. An isolated monoclonal antibody or antigen-binding fragment thereof comprising a light chain complementarity determining region 1 (LCDR1), a LCDR2, a LCDR3, a heavy chain complementarity determining region 1 (HCDR1), a HCDR2, and a HCDR3, having the polypeptide sequences of:(1) SEQ ID NOs: 30, 31, 32, 26, 27, and 28, respectively
(2) SEQ ID NOs: 6, 7, 8, 2, 3, and 4, respectively;
(3) SEQ ID NOs: 14, 15, 16, 10, 11, and 12, respectively;
(4) SEQ ID NOs: 22, 23, 24, 18, 19, and 20, respectively;
(5) SEQ ID NOs: 38, 39, 40, 34, 35, and 36, respectively;
(6) SEQ ID NOs: 46, 47, 48, 42, 43, and 44, respectively; or
(7) SEQ ID NOs: 54, 55, 56, 50, 51, and 52, respectively;
wherein the antibody or antigen-binding fragment thereof binds PD-L1.
US Pat. No. 10,889,649

COMPOSITIONS AND METHODS FOR INDUCING PHAGOCYTOSIS OF MHC CLASS I POSITIVE CELLS AND COUNTERING ANTI-CD47/SIRPA RESISTANCE

The Board of Trustees of ...

1. A composition for increasing phagocytosis of a target cell, the composition comprising:(a) an anti-MHC Class I/leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1) agent; and
(b) at least one of:
(i) an agent that opsonizes the target cell, and
(ii) an anti-CD47/single regulatory protein alpha (SIRPA) agent.
US Pat. No. 10,892,467

NONAQUEOUS ELECTROLYTE SECONDARY BATTERY

SANYO Electric Co., Ltd.,...

7. A nonaqueous electrolyte secondary battery comprising:an electrode assembly including a negative plate and a positive plate including a positive electrode active material mix layer containing a positive electrode active material;
a nonaqueous electrolyte;
a battery case that houses the electrode assembly and the nonaqueous electrolyte; and
a pressure-sensitive safety system that operates when the pressure in the battery case reaches a value greater than or equal to a predetermined value,
wherein the nonaqueous electrolyte contains an electrolyte salt containing fluorine, the positive electrode active material mix layer contains lithium carbonate and lithium phosphate, the average particle size of lithium carbonate contained in the positive electrode active material mix layer is greater than the average particle size of lithium phosphate contained in the positive electrode active material mix layer, and the number of particles of lithium carbonate contained in the positive electrode active material mix layer is less than the number of particles of lithium phosphate contained in the positive electrode active material mix layer, and
wherein the average distance between the neighboring lithium carbonate particles and lithium phosphate particles in the positive electrode active material mix layer is 4 ?m to 20 ?m.
US Pat. No. 10,888,625

DRUG DELIVERY PARTICLE FORMULATIONS WITH TARGETING MOIETIES

PARTICLE SCIENCES, INC., ...

1. A targeted drug delivery complex comprising a particle, a targeting moiety attached electrostatically to the particle, and an active pharmaceutical ingredient dispersed or dissolved with or attached to the particle, wherein the targeting moiety and the active pharmaceutical ingredient are not covalently modified, wherein the particle is made of a matrix comprising cetylpyridinium bromide and a lipid, natural polymer and/or synthetic polymer, and wherein the targeting moiety is selected from an antibody or a Fab.
US Pat. No. 10,889,651

ANTI-LY6E ANTIBODIES AND METHODS OF USE

Genentech, Inc., South S...

1. An in vitro method of detecting human Ly6E in a biological sample comprising contacting the biological sample with an isolated antibody that binds to human Ly6E comprising the amino acid sequence of SEQ ID NO: 38, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:32, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:34, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:29, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:30, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:31, and detecting whether a complex is formed between the anti-Ly6E antibody and the human Ly6E in the biological sample, wherein the method comprises a control, andwherein (i) the antibody is conjugated to a label and detecting the complex comprises detecting the label; or (ii) detecting the complex comprises detecting the antibody with a labeled secondary antibody.
US Pat. No. 10,888,626

LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY

Translate Bio, Inc., Lex...

1. A method for delivery of messenger RNA (mRNA) for in vivo production of a factor IX (FIX) protein, comprising administering, to a human, a composition comprising an mRNA that encodes the FIX protein wherein the mRNA is encapsulated within a lipid nanoparticle, wherein the administering of the composition results in expression of the FIX protein encoded by the mRNA that is detectable in serum at least 72 hours after administration, and wherein the lipid nanoparticle comprises one or more PEG-modified lipids.
US Pat. No. 10,889,652

ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR ROR1

Juno Therapeutics, Inc., ...

1. An anti-human receptor tyrosine kinase-like orphan receptor 1 (ROR1) antibody or an antigen-binding fragment thereof comprising:a heavy chain variable (VH) region comprising a CDR-H1, a CDR-H2, and a CDR-H3 comprising the amino acid sequences set forth in SEQ ID NOs: 20, 21, and 22, respectively, and a light chain variable (VL) region comprising a CDR-L1, a CDR-L2, and a CDR-L3 comprising the amino acid sequences set forth in SEQ ID NOs: 23, 24, and 25 respectively;
a heavy chain variable (VH) region comprising a CDR-H1, a CDR-H2, and a CDR-H3 comprising the amino acid sequences set forth in SEQ ID NOs: 20, 26, and 22, respectively, and a light chain variable (VL) region comprising a CDR-L1, a CDR-L2, and a CDR-L3 comprising the amino acid sequences set forth in SEQ ID NOs: 23, 24, and 25, respectively;
a heavy chain variable (VH) region comprising a CDR-H1, a CDR-H2, and a CDR-H3 comprising the amino acid sequences set forth in SEQ ID NOs: 27, 28, and 29, respectively, and a light chain variable (VL) region comprising a CDR-L1, a CDR-L2, and a CDR-L3 comprising the amino acid sequences set forth in SEQ ID NOs: 218, 229, and 39, respectively;
a heavy chain variable (VH) region comprising a CDR-H1, a CDR-H2, and a CDR-H3 comprising the amino acid sequences set forth in SEQ ID NOs: 27, 28, and 29, respectively, and a light chain variable (VL) region comprising a CDR-L1, a CDR-L2, and a CDR-L3 comprising the amino acid sequences set forth in SEQ ID NOs: 30, 31, and 32, respectively;
a heavy chain variable (VH) region comprising a CDR-H1, a CDR-H2, and a CDR-H3 comprising the amino acid sequences set forth in SEQ ID NOs: 27, 28, and 29, respectively, and a light chain variable (VL) region comprising a CDR-L1, a CDR-L2, and a CDR-L3 comprising the amino acid sequences set forth in SEQ ID NOs: 216, 227, and 40, respectively;
a heavy chain variable (VH) region comprising a CDR-H1, a CDR-H2, and a CDR-H3 comprising the amino acid sequences set forth in SEQ ID NOs: 27, 28, and 29, respectively, and a light chain variable (VL) region comprising a CDR-L1, a CDR-L2, and a CDR-L3 comprising the amino acid sequences set forth in SEQ ID NOs: 219, 230, and 43, respectively;
a heavy chain variable (VH) region comprising a CDR-H1, a CDR-H2, and a CDR-H3 comprising the amino acid sequences set forth in SEQ ID NOs: 33, 34, and 35, respectively, and a light chain variable (VL) region comprising a CDR-L1, a CDR-L2, and a CDR-L3 comprising the amino acid sequences set forth in SEQ ID NOs: 217, 228, and 41, respectively;
a heavy chain variable (VH) region comprising a CDR-H1, a CDR-H2, and a CDR-H3 comprising the amino acid sequences set forth in SEQ ID NOs: 33, 34, and 35, respectively, and a light chain variable (VL) region comprising a CDR-L1, a CDR-L2, and a CDR-L3 comprising the amino acid sequences set forth in SEQ ID NOs: 212, 223, and 42, respectively;
a heavy chain variable (VH) region comprising a CDR-H1, a CDR-H2, and a CDR-H3 comprising the amino acid sequences set forth in SEQ ID NOs: 33, 34, and 35, respectively, and a light chain variable (VL) region comprising a CDR-L1, a CDR-L2, and a CDR-L3 comprising the amino acid sequences set forth in SEQ ID NOs: 36, 37, and 38, respectively;
a heavy chain variable (VH) region comprising a CDR-H1, a CDR-H2, and a CDR-H3 comprising the amino acid sequences set forth in SEQ ID NOs: 33, 34, and 35, respectively, and a light chain variable (VL) region comprising a CDR-L1, a CDR-L2, and a CDR-L3 comprising the amino acid sequences set forth in SEQ ID NOs: 215, 226, and 44, respectively;
a heavy chain variable (VH) region comprising a CDR-H1, a CDR-H2, and a CDR-H3 comprising the amino acid sequences set forth in SEQ ID NOs: 33, 34, and 35, respectively, and a light chain variable (VL) region comprising a CDR-L1, a CDR-L2, and a CDR-L3 comprising the amino acid sequences set forth in SEQ ID NOs: 211, 222, and 48, respectively;
a heavy chain variable (VH) region comprising a CDR-H1, a CDR-H2, and a CDR-H3 comprising the amino acid sequences set forth in SEQ ID NOs: 27, 164, and 45, respectively, and a light chain variable (VL) region comprising a CDR-L1, a CDR-L2, and a CDR-L3 comprising the amino acid sequences set forth in SEQ ID NOs: 220, 231, and 46, respectively;
a heavy chain variable (VH) region comprising a CDR-H1, a CDR-H2, and a CDR-H3 comprising the amino acid sequences set forth in SEQ ID NOs: 33, 318, and 35, respectively, and a light chain variable (VL) region comprising a CDR-L1, a CDR-L2, and a CDR-L3 comprising the amino acid sequences set forth in SEQ ID NOs: 210, 221, and 49, respectively;
a heavy chain variable (VH) region comprising a CDR-H1, a CDR-H2, and a CDR-H3 comprising the amino acid sequences set forth in SEQ ID NOs: 33, 318, and 35, respectively, and a light chain variable (VL) region comprising a CDR-L1, a CDR-L2, and a CDR-L3 comprising the amino acid sequences set forth in SEQ ID NOs: 210, 221, and 233, respectively; or
a heavy chain variable (Vii) region comprising a CDR-H1, a CDR-H2, and a CDR-H3 comprising the amino acid sequences set forth in SEQ ID NOs: 155, 34 and 35, respectively, and a light chain variable (VL) region comprising a CDR-L1, a CDR-L2, and a CDR-L3 comprising the amino acid sequences set forth in SEQ ID NOs: 213, 224, and 47, respectively.
US Pat. No. 10,888,627

NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF

Factor Bioscience Inc., ...

1. An in vivo method for treating cancer in a subject comprising:administering to a tumor cell in the subject a non-viral, cell-free composition comprising a synthetic messenger RNA (mRNA) encoding a gene-editing protein capable of creating a single-strand or double-strand break in an immune checkpoint molecule gene and
causing a single-strand or double-strand break in the DNA of the tumor cell, the single-strand or double-strand break being localized to an immune checkpoint molecule gene in the tumor cell in the subject,
resulting in the stimulation or enhancement of an immune response in the subject, thereby treating cancer in the subject.
US Pat. No. 10,889,653

HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS

Xencor, Inc., Monrovia, ...

1. A heterodimeric antibody comprising:a) a first monomer comprising:
i) a first heavy chain comprising:
1) a first variable heavy domain;
2) a first constant heavy chain comprising a first Fc domain;
3) a scFv comprising a scFv variable light domain, an scFv linker and a scFv variable heavy domain; wherein said scFv is covalently attached to the C-terminus of said Fc domain using a domain linker;
b) a second monomer comprising a second heavy chain comprising a second variable heavy domain and a second constant heavy chain comprising a second Fc domain; and
c) a common light chain comprising a variable light domain and a constant light domain;
wherein said first and said second Fc domains have a set of amino acid substitutions selected from the group consisting of S364K/E357Q:L368D/K370S; L368D/K370S:S364K; L368E/K370S:S364K; T411E/K360E/Q362E:D401K; L368D/K370S:S364K/E357L and K370S:S364K/E357Q,
wherein said first variable heavy domain and said variable light domain bind a first target tumor antigen (TTA), said second variable heavy domain and said variable light domain bind said first TTA, and said scFv binds human CD3, and
wherein said heterodimeric antibody is a trivalent antibody.
US Pat. No. 10,888,628

GENE THERAPY FOR TREATING HEMOPHILIA A

The Trustees of the Unive...

1. A recombinant adeno-associated virus (rAAV) comprising an AAV capsid and a vector genome packaged therein, said vector genome comprising:an AAV 5?-inverted terminal repeat (ITR) sequence;
a liver-specific promoter;
a coding sequence encoding a human Factor VIII having coagulation function; and
an AAV 3?-ITR sequence,
wherein said coding sequence comprises the nucleotide sequence as set forth in SEQ ID NO: 2.
US Pat. No. 10,889,654

ACYLATION PROCESS

SOLVAY ACETOW GmbH, Frei...

1. A process for manufacturing an acylated polysaccharide and recovering a permeate containing carboxylic acid comprising:(a) reacting a polysaccharide with an acylating agent to produce an acylated polysaccharide,
wherein the polysaccharide is cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, and sodium, potassium, calcium or ammonium salts of cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose or starch,
wherein the acylation agent comprises
at least one organic acidic compound selected from the group consisting of acetic anhydride and acetic acid, and
a mineral acid comprising sulphuric acid;
(b) quenching, precipitating and washing the acylated polysaccharide with water containing from 0.05 to 8 mg/l Ca2+-ions; and
(c) recovering the washed acylated polysaccharide and a combined aqueous phase from the quenching, precipitating and washing containing carboxylic acid from step (b), wherein concentration of carboxylic acid in the combined aqueous phase is 5 to 40 wt. %,
wherein the combined aqueous phase is treated by nanofiltration or reverse osmosis to recover a permeate containing carboxylic acid and wherein the process is carried out in the substantial absence of a surface active substance, wherein concentration of the surface-active substance in the combined aqueous phase is equal to or lower than 150 ppm, wherein there is an absence of lignosulfates, wherein all water used to wash the acylated polysaccharide contains from 0.05 to 8 mg/l Ca2+-ions;
wherein the combined aqueous phase contains from 10 to 20000 mg/l SO42?-ions.
US Pat. No. 10,892,472

NONAQUEOUS ELECTROLYTE SECONDARY BATTERY

PANASONIC INTELLECTUAL PR...

1. A non-aqueous electrolyte secondary battery comprising:a positive electrode having a positive electrode mixture layer containing a first positive electrode active material and a second positive electrode active material;
a negative electrode having a negative electrode mixture layer containing a lithium-titanium composite oxide as a negative electrode active material; and
a non-aqueous electrolyte containing a lithium salt having an oxalate complex as an anion, wherein
the first positive electrode active material is a Co-containing lithium transition metal oxide and has a pore volume, of pores each having a pore diameter of 100 nm or less, per mass of 8 mm3/g or more,
the second positive electrode active material has a pore volume, of pores each having a pore diameter of 100 nm or less, per mass of 5 mm3/g or less,
the pore volume, of pores each having a pore diameter of 100 nm or less, per mass of the first positive electrode active material is 4 or more times the pore volume, of pores each having a pore diameter of 100 nm or less, per mass of the second positive electrode active material,
the content of the first positive electrode active material is 30 mass % or less based on the total amount of the first positive electrode active material and the second positive electrode active material, and
the lithium salt having an oxalate complex as an anion is represented by the general formula: Li[M(C2O4)xRy], wherein M is B or P, R is a group selected from a halogen, an alkyl group or a halogen-substituted alkyl group, x is a positive integer, and y is 0 or a positive integer.
US Pat. No. 10,889,655

DESTRUCTURED STARCH DERIVATIVES AND ELASTOMER COMPOSITIONS CONTAINING THEM

NOVAMONT S.P.A., Novara ...

1. A composition comprising at least one elastomer and at least one silyl ether of destructurized starch in which at least one oxygen atom of the destructurized starch is covalently linked with at least one silicon atom and/or at least one silicon-containing compound, said silyl ether being obtained by means of a process comprising the steps of:a. preparing destructurized starch;
b. mixing said destructurized starch with at least one silicon-containing compound at temperatures between 110 and 250° C.;
in which during step a, or after step a and before step b, adding at least one crosslinking agent selected from the group consisting of aldehydes, polyaldehydes and anhydrides;
wherein:
said silicon-containing compound is selected from the group consisting of organosilanes having the general formula selected from:
(RO)3SiCnH2nSmCnSi(OR)3tm (I)
(RO)3SiCnH2nX  (II)
(RO)3SiCnH2nSmY  (III)
in which
“R” represents an alkyl group having from 1 to 4 carbon atoms, the three R being the same or different;
“n” represents an integer from 1 to 6,
“m” represents an integer from 1 to 6;
“X” represents a mercaptane group, an amine group, a vinyl group, a nitroso group, an imide group, a chlorine atom or an epoxy group;
“Y” represents a cyano group, an N,N-dimethyl thiocarbamoyl group, a mercaptobenzothriazole group, or a methacrylate group; and
said elastomer is selected from natural rubbers and synthetic rubbers, and said synthetic rubbers are selected from the group consisting of dienic homopolymers, block copolymers styrene-butadiene-styrene, random copolymers styrene-isoprene, block copolymers styrene-isoprene-styrene, block copolymers acrylonitrile-butadiene, and random copolymers of vinylarene-conjugated dienes.
US Pat. No. 10,892,473

POSITIVE ELECTRODE PLATE AND ELECTROCHEMICAL BATTERY

CONTEMPORARY AMPEREX TECH...

1. A positive electrode plate, comprising:a positive electrode current collector; and
a positive electrode film, the positive electrode film being provided on the positive electrode current collector and comprising a positive electrode active material and a binder;
wherein,
the positive electrode active material comprises a prussian blue analogue material, a molecular formula of the prussian blue analogue material is AxMy[M?(CN)6]z·nH2O, where, A is one or more selected from a group consisting of alkali metal cation, alkaline-earth metal cation, Zn2+ and Al3+, M is a transition metal, M? is a transition metal, 0 the binder is an oil-soluble binder;
an area density of the positive electrode film is 5 mg/cm2˜30 mg/cm2; and
a water content of the positive electrode film is 300 ?g/g˜3000 ?g/g.
US Pat. No. 10,888,631

LIPID STERILIZATION METHOD

GE HEALTHCARE AS, Oslo (...

1. A method of sterilization of a suspension, which comprises:(i) mixing a hydrogenated egg phosphatidylserine together with propylene glycol in an aqueous biocompatible carrier using a mixer of a jacketed vessel to give an aqueous hydrogenated egg phosphatidylserine suspension, wherein the suspension contacts an inner wall of the jacketed vessel and the mixer is provided within the jacketed vessel and is configured to mix the contents of the jacketed vessel;
(ii) autoclaving the aqueous hydrogenated egg phosphatidylserine suspension from step (i), wherein said autoclaving enables reaching F0 values >15 in all parts of the sterilization system, and wherein heating, in addition to sensible heat from heating the jacket of said vessel, comprises the addition of steam to the headspace of the vessel of step (i) to obtain a hot suspension; and
(iii) cooling the hot suspension to 15 to 30° C. to give the sterile hydrogenated egg phosphatidylserine suspension, wherein the mass ratio of phospholipid to propylene glycol is 1:1.5 to 1:2.5.
US Pat. No. 10,889,657

ALGINATE EXTRACTION METHOD

HASKONINGDHV NEDERLAND B....

1. A process for biopolymer extraction for obtaining fibrous biopolymer comprising the steps of(ii) providing an ionic biopolymer aqueous solution, wherein the biopolymer is present in an amount of 0.1-40 wt. %,
(iv) adding, to the solution, 35-60 vol. % of one or more non-solvents, chosen from the group of acetone (dimethylketone), mono- or dialkyl ketones and alkoxy alkanol, under mixing, and
(v) extracting the biopolymer from the solution,wherein weight c.q. volume percentages are relative to a total mass c.q. volume of the final solution.
US Pat. No. 10,888,633

PHASE-STABLE, SPRAYABLE FRESHENING COMPOSITIONS COMPRISING SUSPENDED PARTICLES

1. A sprayable product comprising a spray dispenser and a freshening composition disposed in the spray dispenser, the freshening composition comprising:a plurality of particles comprising a plurality of benefit agent delivery particles having a benefit agent and a wall material encapsulating the benefit agent, wherein the composition comprises from about 0.001% to about 1.0%, by weight of the composition, of the encapsulated benefit agent;
a polysaccharide system comprising a first polysaccharide and a second polysaccharide, wherein the first polysaccharide is xanthan gum, and wherein the second polysaccharide is selected from the group consisting of konjac gum, locust bean gum, and combinations thereof, wherein the xanthan gum has an average ratio of acetylation in the range of about 2.0 to about 0.5; and an aqueous carrier;
wherein the composition has a yield stress of greater than 0 Pa and less than about 1.0 Pa, as measured by the YIELD STRESS AND SPRAY SHEAR VISCOSITY TEST METHOD described herein, wherein the first polysaccharide is present at a level of 40 wt. % to 60 wt. %, by weight of the polysaccharide system; and wherein the total polysaccharide level of the composition is less than about 0.2 wt. % by weight of the composition.
US Pat. No. 10,889,147

RUBBER COMPOSITION COMPRISING A SPECIFIC HYDROCARBONATED RESIN

Compagnie Generale Des Et...

1. A rubber composition comprising at least one diene elastomer, a reinforcing filler, a crosslinking system and an aliphatic hydrocarbon-based resin,wherein said aliphatic hydrocarbon-based resin has a number-average molecular weight Mn of between 700 and 1000 g/mol, an average molecular weight Mz of between 6000 and 8000 g/mol and a polydispersity index PI of greater than 2.4.
US Pat. No. 10,889,660

EMULSIFYING INITIATOR, CORE-SHELL COPOLYMER, AND THERMOPLASTIC RESIN COMPOSITION COMPRISING SAME

LG Chem, Ltd., (KR)

1. A core-shell copolymer comprising:a core including an emulsifying initiator-derived layer derived from an emulsifying initiator, and a core forming monomer-derived repeating unit, bound to the emulsifying initiator-derived layer, and
a shell including a shell forming monomer-derived repeating unit,
wherein a content of the emulsifying initiator-derived layer is 2% by weight to 20% by weight, a content of the core forming monomer-derived repeating unit is 40% by weight to 88% by weight, and a content of the shell forming monomer-derived repeating unit is 10% by weight to 40% by weight, based on a total content of the core-shell copolymer,
the emulsifying initiator comprising a surfactant part, an initiator part, and a vinyl monomer-derived repeating unit, the surfactant part including an organic acid-based monomer-derived repeating unit, and the initiator part including a peroxide-based monomer-derived repeating unit,
wherein a content of the organic acid-based monomer-derived repeating unit is more than 2.5% by weight and less than 40% by weight, a content of the peroxide-based monomer-derived repeating unit is more than 2.5% by weight and less than 40% by weight, and a content of the vinyl monomer-derived repeating unit is more than 20% by weight and less than 95% by weight, based on a total content of the emulsifying initiator, and
wherein the emulsifying initiator has a weight average molecular weight less than 250,000 g/mol.
US Pat. No. 10,889,661

STABLE POLYACRYLIC ACIDS, THEIR MANUFACTURE AND THEIR USE

BASF SE, Ludwigshafen (D...

1. An aqueous composition comprising:(1) a homopolymer selected from the group consisting of:
(a) a homopolymer of acrylic acid, having a molecular weight (Mw) of about 2000 g/mol and a polydispersity of 1.8;
(b) a homopolymer of acrylic acid, having a molecular weight (Mw) of about 5000 g/mol and a polydispersity of 1.8; and
(c) a homopolymer of acrylic acid, having a molecular weight (Mw) of about 8000 g/mol and a polydispersity of 1.9,
wherein the homopolymer is in acid form and has not been neutralized, and is characterized by superior rheological performance in a mineral slurry relative to a reference homopolymer of acrylic acid of comparable molecular weight and polydispersity, wherein the reference homopolymer is a fully neutralized polymer;
and
(2) a filler selected from kaolin, talc, clay, white carbon, aluminum hydroxide, titanium dioxide, calcium carbonate, calcite, marble, or a mixture thereof,
wherein the aqueous composition is a slurry.
US Pat. No. 10,888,636

CURABLE CALCIUM PHOSPHATE COMPOSITIONS FOR USE WITH POROUS STRUCTURES AND METHODS OF USING THE SAME

ZIMMER KNEE CREATIONS, IN...

1. An apparatus comprising:a porous metal structure comprising
a porous substrate comprising a plurality of ligaments that define pores of the porous substrate, and
a biocompatible metal coating on the plurality of ligaments of the porous substrate; and
a curable calcium phosphate composition or a cured product thereof at least partially in contact with the porous metal structure and injection-perfused into the pore space of the porous metal structure to a depth of greater than 6 mm from a surface of the porous metal structure and greater than 10 pore diameters from the surface of the porous metal structure, the curable calcium phosphate composition comprising
calcium phosphate,
a perfusion modifier, wherein the perfusion modifier is 0.5 wt % to 5 wt % of the curable calcium phosphate composition, wherein the perfusion modifier is methylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, a salt thereof or a combination thereof, and
a physiologically acceptable fluid.
US Pat. No. 10,888,638

METHOD FOR PRODUCING A COLLAGEN MEMBRANE AND USES THEREOF

Orthocell Limited

1. A method of producing a collagen-containing membrane, the method comprising the steps of:(i) incubating an isolated collagen-containing tissue comprising collagen bundles in an ethanol solution;
(ii) incubating the collagen-containing tissue from step (i) in a solution comprising an inorganic salt selected from the group consisting of trimethylammonium chloride, tetramethylammonium chloride, sodium chloride, lithium chloride, perchlorate and trifluoromethanesulfonate and an anionic surfactant selected from the group consisting of alkyl sulfates, alkyl ether sulfates, alkyl sulfonates, and alkyl aryl sulfonates in order to denature non-collagenous proteins contained therein;
(iii) incubating the collagen-containing tissue produced in step (ii) in a solution comprising HCl until the collagen in said tissue is denatured; and
(iv) manipulating the collagen-containing tissue produced in step (iii) using simultaneous mechanical stimulation for sufficient time to enable the collagen bundles in said collagen-containing tissue to align and incubating said tissue in a solution comprising an HCl until the collagen-containing membrane is produced;
wherein the mechanical stimulation comprises applying tension cyclically to the collagen-containing tissue.
US Pat. No. 10,889,664

SURFACTANT AS TITANATION LIGAND

Chevron Phillips Chemical...

1. A method consisting of contacting a silica support with a titanium-containing solution to form a titanated silica support, wherein the titanium-containing solution consists of a titanium compound, a solvent, a carboxylate, and a surfactant, wherein the titanium-containing solution has a pH of less than about 5.5, wherein the surfactant comprises a water-insoluble component and a water-soluble component, wherein the titanium-containing solution comprises from about 5 wt. % to about 15 wt. % of the surfactant, based on weight of the surfactant and weight of the titanium, and wherein the aqueous titanium solution comprises an equivalent molar ratio of the carboxylate to the titanium compound in a range of from about 1 to about 4.
US Pat. No. 10,888,896

ACTIVATION METHOD USING MODIFYING AGENT

THE BOEING COMPANY, Chic...

1. A method of activating an aged or inert organic coating to enhance adhesion of the coating to a further coating and/or to other entities selected from adhesives, sealants, pin hole fillers or pressure sensitive decals or logos comprising applying an organic solvent and a surface chemistry and/or surface topography modifying agent which facilitates surface reduction, to a surface of the aged or inert organic coating.
US Pat. No. 10,889,665

PROCESS FOR FUNCTIONALIZING A BIOCOMPATIBLE POLYMERIC BEAD, THE FUNCTIONALIZED BEADS, AND THE BEADS PRODUCED THEREBY

CYTOSORBENTS, INC., Monm...

1. A process for making a polymeric bead having an epoxide group with a biological molecule attached thereto on its surface, said polymeric beads comprising pores having an average diameter of less than 200 Angstroms, comprising simultaneously contacting a polymeric bead which comprises monomeric divinylbenzene and has pores having an average diameter of less than 200 Angstroms with acetic acid and hydrogen peroxide to form an epoxide group on the surface of said polymeric beads, and attaching a biological molecule to said epoxide group.
US Pat. No. 10,890,689

SILICONE HYDROGELS COMPRISING POLYAMIDES

1. A silicone hydrogel formed from a reactive monomer mixture comprising:a) between about 1 and about 15 wt % at least one polyamide;
b) at least one first mono-functional hydroxyl substituted, poly(disubstituted siloxane) having 4 to 8 siloxane repeating units;
c) at least one second hydroxyl substituted poly(disubstituted siloxane) comprising a mixture of a mono-functional hydroxyl substituted poly(disubstituted siloxane) having 10 to 200 siloxane repeating units and a multifunctional hydroxyl substituted poly(disubstituted siloxane) having 10 to 200 siloxane repeating units;
d) about 5 to about 35 wt % of at least one hydrophilic monomer;
wherein the first mono-functional hydroxyl substituted, poly(disubstituted siloxane) and the second hydroxyl substituted poly(disubstituted siloxane) are present in concentrations to provide a ratio of wt % of all first mono-functional hydroxyl substituted, poly(disubstituted siloxane) to wt % of all second hydroxyl substituted poly(disubstituted siloxane of 0.4-1.3.
US Pat. No. 10,889,666

MOLECULAR MODIFICATION OF POLYETHYLENE RESIN

BOREALIS AG, Vienna (AT)...

1. A process for obtaining a controlled reduction of the melt flow rate (5 kg, 190° C.) (MFR) of a polyethylene by modifying the polyethylene, wherein the polyethylene comprises recycled polyethylene and is a homopolymer or is a copolymer containing from 0.1 to 30% by mole of comonomer(s), the polyethylene having a starting melt flow rate (5 kg, 190° C.) (MFR0) and a melting temperature, the process comprising the steps of:(a) determining the starting melt flow rate (5 kg, 190° C.) (MFR0) of the polyethylene,
(b) feeding the polyethylene into an extrusion device comprising a feed zone, a melting zone, a mixing zone, and a die zone,
(c) feeding a peroxide into the extrusion device, wherein the peroxide is provided in an amount of X ppm over the weight of the polyethylene, wherein the amount of peroxide X is in a range of 300 ppm to 4000 ppm,
(d) mixing the polyethylene with the peroxide in the extrusion device at a temperature above the melting point of the polyethylene to form a mixture that is substantially homogeneous,
(e) extruding the mixture obtained from step (d) to provide a modified polyethylene having a final melt flow rate (5 kg, 190° C.) (MFRf),
(f) determining the final melt flow rate (5 kg, 190° C.) (MFRf) of the modified polyethylene obtained from step (e),
characterized in that:
the mixture comprising the polyethylene and the peroxide is heated to a temperature in the range of from 170 to 250° C.;
the overall average residence time in the combined melting zone and mixing zone of the extruder is from 15 to 60 seconds;
the final melt flow rate (5 kg, 190° C.) (MFRf) of the modified polyethylene fulfills an exponential decay defined by equation (I) with respect to the starting melt flow rate (5 kg, 190° C.) (MFR0) and the concentration (X) of the peroxide based on the amount of polyethylene,
MFRf=MFR0×e??X  (I)
wherein ? is an exponential decay constant and is from 0.0005 to 0.005; and
the final melt flow rate (MFRf) of the modified polyethylene is in the range of from 0.1 to 8.0 g/10 min; and
wherein the process further comprises the steps of:
defining a target melt flow rate (5 kg, 190° C.) (MFRt) for the modified polyethylene,
determining the value of ? in equation (I) using the starting melt flow rate MFR0, the final melt flow rate MFRf, and the amount of the peroxide X for the combination of the polyethylene, the peroxide, the temperature at which the mixture comprising the polyethylene and the peroxide is heated, and the overall average residence time in the combined melting zone and mixing zone of the extruder,
using the determined value of ?, the starting melt flow rate MFR0, the target melt flow rate MFRt, and equation (II) to determine the amount of peroxide (X) required to achieve the target melt flow rate,
MFRt=MFR0×e??X  (II), and
feeding the required amount of peroxide X determined from equation (II) for achieving the target melt flow rate into the extrusion device in step (c), such that the final melt flow rate of the modified polyethylene is the target melt flow rate.
US Pat. No. 10,892,485

ELECTRODE MATERIAL FOR LITHIUM ION SECONDARY BATTERY, ELECTRODE MATERIAL GRANULATED BODY FOR LITHIUM ION SECONDARY BATTERY, ELECTRODE FOR LITHIUM ION SECONDARY BATTERY, AND LITHIUM ION SECONDARY BATTERY

SUMITOMO OSAKA CEMENT CO....

1. An electrode material for a lithium ion secondary battery comprising:an electrode active material; and
a carbonaceous film that coats a surface of the electrode active material,
wherein a hydroxy group, a carboxyl group, a nitro group and a sulfo group have been introduced to an outermost surface of the carbonaceous film,
a ratio of a total count number of the carboxyl group, the nitro group and the sulfo group, to a count number of the hydroxy group is 0.001 or more and 10.000 or less, when the outermost surface of the carbonaceous film is analyzed through time-of-flight secondary ion mass spectrometry to obtain the ratio,
a coating ratio of the carbonaceous film is 40% or more and 90% or less,
the carbonaceous film has at least one through-hole per 100 square nanometers of the carbonaceous film
an average film thickness of the carbonaceous film is 1.0 nm or more and 7.0 nm or less, and
a specific surface area of the electrode material is 5 m2/g or more and 40 m2/g or less.
US Pat. No. 10,889,667

HIGH-STIFFNESS AND ENERGY-REDUCING POLYPROPYLENE FOR FOAMING

LG CHEM, LTD., Seoul (KR...

1. A polyethylene polypropylene having:a melt index (MI), measured at 230° C. under a load of 2.16 kg according to ASTM D1238, of 4 to 60 g/10 min,
a melting point (Tm) of 130° C. to 140° C.,
a flexural modulus, measured according to ASTM 790, of 9,000 to 18,000 kgf/cm2, and
a crystallization temperature of 80° C. to 105° C.
US Pat. No. 10,889,924

METHOD FOR MANUFACTURING POLYESTER FILAMENT SPUN-BONDED NON-WOVEN FABRIC

1. A method for manufacturing polyester filament spun-bonded non-woven fabric, wherein the polyester filament spun-bonded non-woven fabric is prepared by the following steps:i) preparation of raw material: drying some polyester chips and black color masterbatch respectively, wherein the polyester chips account for 95-98% and the black masterbatch accounts for 2-5%;
ii) conveying the dried polyester chips and the dried black color masterbatch to a screw extruder for being melted and compressed into a viscous melt, and making the melt pass through a melt filter to remove impurities and obtain filtered melt;
iii) evenly distributing the filtered melt into each metering pump through a spinning manifold, wherein the spinning manifold maintains 297° C. to 299° C., the metering pump outputs the melt at 9.08-9.11 m/min, cooling the output melt into filaments under the action of cooling air; drawing the filaments by airflow to obtain drawn filaments and laying the drawn filaments into fiber web; and preliminarily ironing and flattening the fiber webby a pre-pressing roller and then repeatedly punching the fiber web by a needle with a groove on the edge to obtain a fiber web-reinforced non-woven fabric;
iv) winding the non-woven fabric obtained through the punching process in step by a winder and then shaping the non-woven fabric by a hot mill to obtain the polyester filament spun-bonded non-woven fabric;
wherein a revolving speed of the screw extruder in step ii) is 40-42 r/min, and temperature conditions required for melting and compressing are as follows: the screw extruder is divided into a cold zone, zone 1, zone 2, zone 3, zone 4, zone 5, zone 6 and zone 7, wherein the cold zone is 46 to 48° C., zone 1 is 280 to 290° C., zone 2 is 282 to 292° C., zone 3 is 284 to 294° C., zone 4 is 286 to 296° C., zone 5 is 288 to 298° C., zone 6 is 289 to 299° C. and zone 7 is 287 to 297° C. respectively.
US Pat. No. 10,889,669

MODULATING INTERFACIAL WETTABILITY OF A NONCOVALENT NANOSCOPIC LIGAND FILM

Purdue Research Foundatio...

1. A method for modulating interfacial wettability of a two-dimensional (2D) material using a molecular layer prepared from a polymerizable amphiphilic monomer having a hydrophilic head and a hydrophobic tail, the method comprising the steps ofa. preparing an amphiphilic monomer, allocating a proper position for the polymerizable group, relative to the hydrophilic head and the hydrophobic tail of said amphiphilic monomer;
b. assembling a monolayer or thin film of said amphiphilic monomer; and
c. polymerizing said amphiphilic monomer whereby affording said 2D material with a nanoscale enhanced or decreased wettability controlled by said amphiphilic monomer.
US Pat. No. 10,889,671

ULTRA PURE RUBBER AND METHOD THEREOF

ARLANXEO SINGAPORE PTE. L...

1. A process for the preparation of an aqueous slurry comprising a plurality of copolymer particles suspended therein, the process comprising:a) providing a reaction medium comprising an organic diluent, and at least two monomers whereby at least one monomer is an isoolefin and at least one monomer is a multiolefin;
b) polymerizing the monomers within the reaction medium in the presence of an initiator system to form a medium comprising the copolymer, the organic diluent and optionally residual monomers; and
c) contacting the medium obtained in step b) with an aqueous medium comprising at least one lower critical solution temperature (LCST) compound having a cloud point of 0 to 100° C., and removing at least partially the organic diluent and to the extent present in the medium removing at least partially the residual monomers to obtain the aqueous slurry comprising the copolymer particles;
wherein the amount of the LCST compounds in the aqueous medium employed in step c) is from 1 to 20,000 ppm with respect to the amount of copolymer present in the medium obtained according to step b).
US Pat. No. 10,889,672

PREPOLYMERIZED RESIN AND USE THEREOF

Elite Electronic Material...

1. A prepolymerized resin prepared from a prepolymerization reaction of a composition, the composition at least comprising: (1) t-butyl styrene; and (2) unsaturated bond-containing polyphenylene oxide, wherein the prepolymerized resin contains a reactive vinyl group.
US Pat. No. 10,889,673

SUPER ABSORBENT POLYMER AND PREPARATION METHOD THEREOF

LG Chem, Ltd.

1. A preparation method of a super absorbent polymer, comprising:preparing a monomer composition including a water-soluble ethylene-based unsaturated monomers have un-neutralized acidic groups, and a polymerization initiator, wherein the polymerization initiator has a content of 40 to 300 ppm based on the amount of water-soluble ethylene-based unsaturated monomers;
adding a neutralizing agent to the monomer composition to neutralize at least some of the un-neutralized acidic groups of the water-soluble ethylene-based unsaturated monomers;
preparing a hydrogel polymer by polymerizing the monomer composition, wherein a polymerization temperature ranges from 20 to 45° C.;
drying the hydrogel polymer;
pulverizing the dried polymer to form particles; and
surface cross-linking the particles in the presence of a surface cross-linking agent to form surface cross-linked polymer particles of the super absorbent polymer, wherein the surface cross-linking agent is present in an amount ranging from 0.15 to 0.7 wt % based on an amount of the particles.
US Pat. No. 10,888,905

HAZARDOUS MATERIAL STORAGE REPOSITORY IN A SUBTERRANEAN FORMATION

Deep Isolation, Inc., Be...

1. A hazardous material storage repository, comprising:a drillhole that extends into the Earth from a terranean surface, the drillhole comprising an entry at least proximate the terranean surface, the drillhole comprising a substantially vertical drillhole portion and a hazardous material storage drillhole portion that is coupled to the substantially vertical drillhole portion and formed in a subterranean salt formation;
a storage canister positioned in the hazardous material storage drillhole portion, the storage canister sized to fit from the drillhole entry through the substantially vertical drillhole portion, and into the hazardous material storage drillhole portion of the drillhole, the storage canister comprising an inner cavity sized to enclose nuclear waste material; and
a seal positioned in the drillhole, the seal isolating the hazardous material storage drillhole portion of the drillhole from the entry of the drillhole.
US Pat. No. 10,889,674

METHOD OF PREPARING A GRAFTED COPOLYMER OF LIGNIN AND/OR CELLULOSE

BIOFIBER TECH SWEDEN AB, ...

1. A method of preparing a grafted copolymer of lignin and/or cellulose, wherein said method comprises the steps of:subjecting a lignin and/or cellulose containing material selected from the group consisting of wood chips and pulp, in an oxygen reduced environment to a redox initiator,
exposing said lignin and/or cellulose containing material to mechanical impact, and
subjecting said lignin and/or cellulose containing material to monomers and/or polymers before, during and/or immediately after exposure to mechanical impact,
wherein macroradicals are generated in situ by mechanical impact on the backbone of the lignin and/or cellulose of said lignin and/or cellulose containing material, and
wherein the monomers and/or polymers are grafted to the backbone of said lignin and/or cellulose.
US Pat. No. 10,889,676

METHOD FOR SYNTHESIZING A THERMOPLASTIC ELASTOMER COMPRISING AT LEAST ONE POLY(?-METHYLSTYRENE) BLOCK

COMPAGNIE GENERALE DES ET...

1. A method for synthesizing a thermoplastic elastomer comprising at least one polydiene block and at least one other poly(?-methylstyrene) block, wherein the method comprises the following steps:1. polymerizing at least one diene monomer in a starting reaction medium comprising an anionic polymerization initiator and an aprotic non-polar solvent to obtain a living polydiene chain;
2. polymerizing ?-methylstyrene to the living polydiene chain obtained in the preceding step comprising:
a. at the end of the polymerization of step 1., maintaining a reaction medium containing the living polydiene chain obtained previously and ?-methylstyrene at a temperature above 20° C. and below the ceiling temperature for the polymerization of ?-methylstyrene for at least one minute;
b. cooling the reaction medium obtained at the end of the preceding step a., to a temperature below 0° C.;
c. simultaneously, successively or prior to the cooling step, adding a purified aprotic polar solvent to the reaction medium with a volume ratio of the polar solvent to the non-polar solvent of less than 1; and
d. propagating the polymerization of ?-methylstyrene to the living polydiene chain;
3. terminating the polymerization and recovering the thermoplastic polymer.
US Pat. No. 10,890,701

LAMINATE, METHOD OF PRODUCING THE SAME, POLARIZING PLATE, LIQUID CRYSTAL DISPLAY DEVICE, AND ORGANIC EL DISPLAY DEVICE

FUJIFILM Corporation, To...

1. A laminate comprising:a polarizer; and
a photo alignment film that is adjacently arranged on the polarizer,
wherein the photo alignment film is formed by first bringing a composition for forming the photo alignment film into direct contact with a surface of the polarizer, to form a coating film on the surface of the polarizer,
wherein the composition for forming the photo alignment film contains Compound A having a photo-aligned group and Compound B having a crosslinking group, or Compound C having a photo-aligned group and a crosslinking group,
wherein the Compound B or the Compound C is bonded to the polarizer via the crosslinking group,
wherein the crosslinking group is a (meth)acryloyl group or a boronic acid group,
wherein the coating film is cured via a reaction between crosslinking groups in the composition, and a reaction of the polarizer and the crosslinking group of the Compound B or the Compound C, and
wherein the coating film is photo-aligned by subjecting the photo-aligned group of the Compound A or the Compound C to a photo alignment treatment.
US Pat. No. 10,892,496

CATALYST FOR SOLID POLYMER FUEL CELL AND PRODUCTION METHOD FOR THE SAME

TANAKA KIKINZOKU KOGYO K....

1. A catalyst for a solid polymer fuel cell, comprising catalyst particles composed of platinum or a platinum alloy supported on a carbon powder carrier,wherein the catalyst has sulfo functional groups (—SO3H) that are directly bonded to the catalyst particles,
wherein the catalyst further has a fluorine compound having a C—F that is formed separately from the sulfo functional groups and directly bonded to the catalyst particles, and
wherein sulfur (S) content is 800 ppm or more and 5000 ppm or less based on the mass of the whole catalyst.
US Pat. No. 10,889,679

POLYURETHANE HYBRID POLYMERS AND PROCESS FOR THE PRODUCTION THEREOF

Covestro Deutschland AG, ...

1. A method for preparing polyurethane hybrid polymers, comprising reacting polyisocyanates (A) with compounds (B) bearing isocyanate-reactive groups and optionally with chain extenders and/or crosslinkers (C) and optionally in the presence of a catalyst (D) and optionally auxiliaries and/or additives (E) in a molar ratio of NCO groups to OH and/or NH groups of 0.8:1 to 3.5:1, whereini) the polyisocyanate (A) is an NCO prepolymer having an NCO content of 10% to 40% by weight,
which is prepared from at least one polyisocyanate (A?) comprising at least one of aliphatic or aromatic polyisocyanates and at least one polyol component (B?) comprising at least one of a polystyrene polyol having a number-average molecular weight of >1000 g/mol or a polyacrylonitrile polyol having a number-average molecular weight of >2000 g/mol and having the formula below and prepared as shown below:
2nRCH?CH2+H—[O—R?-]mO—C(O)—R?—S—C(S)—S—R?—C(O)—O[—R?—O]m?—H?H—[O—R?-]mO—C(O)—R?—[CH2—CH(R)—]nS—C(S)—S—[—CH2—CH(R)—]n?—R?—C(O)—O [—R?—O]m?—H
wherein R represents an aromatic radical C6H5 or a nitrile radical CN, n, n?, m, and m? are each an integer ?1, and R? and R? independently are alkylene radicals, and optionally at least one further polyol (B?) comprising at least one of polyester polyols, polyether polyols, or polyetherester polyols, and
ii) the compound (B) bearing isocyanate-reactive groups that is used is at least one compound comprising at least one of polyester polyols, polyether polyols, polyetherester polyols, or amino-terminated polyethers.
US Pat. No. 10,889,680

CESIUM AND RUBIDIUM DERIVATIVES AS CATALYSTS FOR POLYURETHANE FOAMS

FXI, Inc., Radnor, PA (U...

1. A method of making a flexible polyurethane foam, comprising:(a) preparing a mixture comprising at least one hydroxyl group-containing compound and a catalyst selected from the group consisting of cesium fluoride, rubidium fluoride and mixtures thereof, wherein the catalyst is present in an amount from 0.1 to 0.5 pph by weight based on parts of polyol; and
(b) reacting the mixture with at least one isocyanate.
US Pat. No. 10,892,242

RESIN COMPOSITION, CONDUCTIVE COPPER PASTE, AND SEMICONDUCTOR DEVICE

NAMICS CORPORATION, Niig...

1. A resin composition, comprising:(A) a copper powder having an oxygen content of 0.3% by mass or less;
(B) a thermosetting resin;
(C) a fatty acid; and
(D) an amine or an amine compound,
wherein the (B) component is at least one selected from the group consisting of an epoxy resin, a Novolac-type phenolic resin, a melamine resin, a xylene resin, and a urea resin.
US Pat. No. 10,889,681

POLYURETHANE CATALYST AND APPLICATION THEREOF

1. A polyurethane catalyst, comprising a sodium compound which accounts for 1-60 wt % by weight of the polyurethane catalyst; wherein the sodium compound is sodium hyaluronate.
US Pat. No. 10,889,683

N,N?-DIAMINOPROPYL-2-METHYLCYCLOHEXANE-1,3-DIAMINE AND N,N?-DIAMINOPROPYL-4-METHYLCYCLOHEXANE-1,3-DIAMINE AND THE USE THEREOF AS CURING AGENTS FOR EPOXY RESINS

BASF SE, Ludwigshafen am...

1. A polyamine, selected from the group consisting of N,N?-diaminopropyl-2-methylcyclohexane-1,3-diamine and N,N?-diaminopropyl-4-methyl-cyclohexane-1,3-diamine.
US Pat. No. 10,889,687

POLYMERIZABLE COMPOSITIONS, POLYMERIZED COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME

3M Innovative Properties ...

1. A polymerizable composition comprising:an organoborane-base complex that is a complex of an organoborane and a base,
wherein the organoborane is represented by the formula B(R1)(R2)(R3) wherein:
R1 represents an alkyl group having from 1 to 10 carbon atoms; and R2 and R3 independently represent: alkyl groups having 1 to 10 carbon atoms; cycloalkyl groups having 3 to 10 carbon atoms; aryl groups having 6 to 12 carbon atoms; or aryl groups substituted with alkyl groups having 1 to 10 carbon atoms or cycloalkyl groups having 3 to 10 carbon atoms, or any two of R1, R2, and R3 taken together form a divalent alkylene group having from 3 to 7 carbon atoms, and
wherein the base is a complexing agent selected from a compound having one or more functional groups selected from the group consisting of amine groups, amidine groups, hydroxide groups, alkoxide groups, and combinations thereof;
a decomplexing agent that at least partially liberates the organoborane from the organoborane-base complex;
a polymerizable thiol-containing component comprising at least one polymerizable thiol-containing compound having a plurality of thiol groups in which the sulfur atom of the thiol group is covalently bonded to carbon;
a hydroperoxide; and
a polymerizable ethylenically-unsaturated component comprising at least one polymerizable ethylenically-unsaturated compound having a plurality of ethylenically-unsaturated groups;
wherein the combined amounts of the thiol-containing and ethylenically-unsaturated compounds total at least 50 percent by weight of all polymerizable material in the polymerizable composition.
US Pat. No. 10,889,689

DESALINATION OF POLYARYL ETHERS BY MEANS OF MELT EXTRACTION

BASF SE, Ludwigshafen am...

1. A process for preparing a polyaryl ether having a softening temperature TS, comprising the steps ofI) reacting the components
(a1) at least one aromatic dihydroxyl compound and
(a2) at least one aromatic sulfone compound having, two halogen substituents
in the presence of a carbonate compound (C) at a first temperature T1-I above the softening temperature TS of the polyaryl ether in a mixing kneader to obtain a salt-containing polymer (SP) comprising the polyaryl ether and a salt (S),
II) transferring the salt-containing polymer (SP) obtained in step I) from the mixing kneader into a reactor comprising a dynamic mixer, where the salt-containing polymer (SP) has a second temperature T2-II above the softening temperature TS of the polyaryl ether, and where the reactor comprises an extractant (E) having a third temperature T3-II above the softening Temperature TS of the polyaryl ether,
III) extracting the salt (S) from the salt-containing polymer (SP) with the extractant (E) in the reactor comprising a dynamic mixer at a fourth temperature T4-III above the softening temperature TS of the polyaryl ether to obtain a desalinated polymer (DP) comprising the polyaryl ether and a salt-containing extractant (SE) comprising the extractant (E) and the salt (S).
US Pat. No. 10,889,690

SILOXANE MONOMERS, THEIR POLYMERIZATION AND USES THEREOF

Inkron Oy, Espoo (FI)

6. A polymer obtained by hydrolysis and polymerization 1,5-Dimethyl-1,1,5,5-tetramethoxy-3,3-bis(p-phenoxyphenyl)-trisiloxane with one, two or three of the following siloxane monomers A, B, C having a corresponding formula I, IIa amd IIb:wherein siloxane monomer A comprises the formula:
(Ph-O-Ph)2Si(X)2   (I)
wherein each X is a hydrolysable group independently selected from hydrogen and lower alkoxy, optionally containing an alkoxy substituent, halo, hydroxy or -OSiMe3;
and
wherein siloxane monomer B comprises the formula:
PhOPh-Si(X)3   (IIa)
wherein each X is a hydrolysable group independently selected from hydrogen and lower alkoxy, optionally containing an alkoxy substituent, halo, hydroxy or -OSiMe3.
and
wherein siloxane monomer C comprise the formula:
PhOPhOPh-Si(X)3   (IIb)
wherein each X is a hydrolysable group independently selected from hydrogen and lower alkoxy, optionally containing an alkoxy substituent, halo, hydroxy or -OSiMe3.
US Pat. No. 10,889,692

TRIBLOCK COPOLYMERS

3M Innovative Properties ...

1. A triblock copolymer of the formula ABC whereinB is a hydrogenated vinyl aromatic block having a Tg of ?110° C. and comprising 30-90 wt. % of the copolymer;
C is a rubbery block having a Tg?25° C. and comprising 10-70 wt. % of the copolymer; and
A is an block derived from ring-opening polymerization, substantially incompatible with both B and C blocks
wherein B+C comprises 70-95 wt. % of the copolymer.
US Pat. No. 10,889,693

EMULSIFIED OILS

Ohio Soybean Council, Wo...

1. A composition comprising:a cationic modified oil alkyl ester, modified oil aryl ester, or combinations thereof, the cationic modified oil alkyl ester or modified oil aryl ester comprising a neutralized transesterification reaction product of an oil and a poly(N,N dimethyl ethyl methacrylate) having a hydroxyl group.
US Pat. No. 10,889,695

TOW PREPREG, COMPOSITE MATERIAL-REINFORCED PRESSURE VESSEL, AND METHOD OF PRODUCING COMPOSITE MATERIAL-REINFORCED PRESSURE VESSEL

Mitsubishi Chemical Corpo...

1. A tow prepreg comprising a reinforcing fiber bundle impregnated with a matrix resin composition, whereinthe matrix resin composition contains a component (A), a component (B), a component (C), and a component (D), wherein
the component (A) is an epoxy resin, the component (B) is dicyandiamide, the component (C) is a curing accelerator, and the component (D) is a core-shell rubber particle and
a content of the component (D) with respect to 100 parts by mass of the component (A) is from 22.7 to 70 parts by mass,
a viscosity of the matrix resin composition is from 3 Pas to 80 Pa·s at 30° C., and
a minimum viscosity to be obtained when a viscosity of the matrix resin composition is measured by raising a temperature from room temperature to 130° C. at a rate of temperature rise of 2.0° C./min is from 0.04 Pa·s to 1 Pa·s.
US Pat. No. 10,889,696

MICROPARTICLES HAVING A MULTIMODAL PORE DISTRIBUTION

Kimberly-Clark Worldwide,...

1. A microparticle comprising a polymeric material, wherein the polymeric material is formed froma thermoplastic composition containing a continuous phase that includes a matrix polymer and a polymeric microinclusion additive and a polymeric nanoinclusion additive dispersed within the continuous phase in the form of discrete domains, wherein the polymeric microinclusion additive is dispersed in the form of discrete micro-scale domains and the polymeric nanoinclusion additive is dispersed in the form of discrete nano-scale domains, further
wherein a porous network is defined in the material that contains a plurality of nanopores and micropores, the nanopores being adjacent to the nano-scale domains and/or the micro-scale domains;
wherein the average pore volume of the material is from about 15% to about 80% per cm3;
wherein the polymeric microinclusion additive constitutes from 0.1 wt. % to 20 wt. % of the composition, based on the weight of the thermoplastic composition and has an average cross-sectional dimension of from about 1 to about 50 micrometers, wherein the microinclusion additive has an average axial dimension that is greater than the average cross-sectional dimension, and wherein the polymeric nanoinclusion additive constitutes from 0.01 wt. % to 15 wt. % of the composition, based on the weight of the thermoplastic composition; and
wherein the microparticle has a spherical shape or a flake shape.
US Pat. No. 10,889,697

POLYETHYLENE COMPOSITION FOR PIPE APPLICATIONS WITH IMPROVED SAGGING AND EXTRUSION PROPERTIES

ABU DHABI POLYMERS CO. LT...

1. Polyethylene composition consisting of:a base resin (A) comprising
a copolymer of ethylene and at least one comonomer selected from alpha-olefins having from three to twelve carbon atoms,
wherein the ethylene copolymer comprises a low molecular weight component (A-1) and a high molecular weight component (A-2) with the low molecular weight component (A-1) having a lower weight average molecular weight than the high molecular weight component (A-2),
(B) carbon black in an amount of 1.0 to 10 wt % based on the total amount of the polyethylene composition, and
(C) optional further additives other than carbon black which are antioxidants, metal scavengers, UV stabilizers, or antistatic agents;
wherein the low molecular weight component (A-1) has a melt flow rate MFR2 (190° C., 2.16 kg) of equal to or more than 150 g/10 min to equal to or less than 400 g/10 min, determined according to ISO 1133,
the base resin (A) has a density of equal to or more than 943 kg/m3 to equal to or less than 957 kg/m3, determined according to ISO 1183, and
the composition has a melt flow rate MFR5 (190° C., 5 kg) of equal to or more than 0.14 g/10 min to equal to or less than 0.30 g/10 min, determined according to ISO 1133, the composition has a complex viscosity at the frequency of 0.05 rad/s, eta0.05, of 170 kPa*s to 270 kPa*s, a viscosity at a constant shear stress of 747 Pa, eta747, of equal to or more than 800 kPa*s to equal to or less than 1300 kPa*s, and complies with the in-equation (I)
eta747[kPa*s]>?1800×MFR5[g/10 min]+1200  (I)
with eta747 referring to said viscosity at a constant shear stress of 747 Pa of the polyethylene composition and MFR5 referring to said melt flow rate MFR5 (190° C., 5 kg) of the polyethylene composition; and
the composition has a flow rate ratio FRR21/5, being the ratio of melt flow rate MFR21 (190° C., 21.6 kg) to melt flow rate MFR5 (190° C., 5 kg), determined according to ISO 1133, of 30 to 40.
US Pat. No. 10,888,929

SHEET AND COMPOSITE SHEET

NITTO DENKO CORPORATION, ...

1. A sheet comprising a pre-sintering layer,wherein the pre-sintering layer comprises polycarbonate and metal particles,
wherein the metal particles have a property such that they become a sintered body when a temperature of the metal particles is increased from 80° C. to 300° C. at a temperature rise rate of 1.5° C./second and is held at 300° C. for 2.5 minutes,
wherein the polycarbonate has a property such that carbon concentration is not greater than 15 wt % following an increase in temperature from 23° C. to 400° C. at a temperature rise rate of 10° C./min in air,
wherein a DTA curve for the pre-sintering layer plotted by TG-DTA from 23° C. to 500° C. at a temperature rise rate of 10° C./min in air has at least one peak between 150° C. and 350° C. but has no peak in a range above 350° C.,
wherein the pre-sintering layer further comprises a binder that has a boiling point between 100° C. and 350° C., wherein two faces of the pre-sintering layer are defined such that there is a first face and a second face opposite the first face; and further comprising a first release liner arranged over the first face; and a second release liner arranged over the second face.
US Pat. No. 10,888,416

THREE DIMENSIONAL TISSUE PRINTING DEVICE, THREE DIMENSIONAL TISSUE PRINTING METHOD AND ARTIFICIAL SKIN

INDUSTRIAL TECHNOLOGY RES...

1. A three dimensional tissue printing device, comprising:a three dimensional moving platform;
an instillation unit connected to the three dimensional moving platform, wherein the instillation unit comprises:
a large support stand printing device configured to fill a temperature-reaction type material further comprising a temperature-controlled modulation module;
a small support stand printing device configured to fill a material;
a driving-sliding platform;
a driving motor, connected to the driving-sliding platform, wherein the temperature-controlled modulation module is furnished at the driving-sliding platform; and
an injection device, further comprising:
an injection barrel furnished into the temperature-controlled modulation module;
a pinhead, furnished at an end of the injection barrel; and
an injection push rod, with an end thereof pivotally furnished at the injection barrel and the other end thereof connected to the driving-sliding platform;
a carrier unit connected to the three dimensional moving platform and positioned opposite to the instillation unit, the carrier unit having a heating element; and
an electric field auxiliary system which is coupled to the injection device and the carrier unit, the electric field auxiliary system further comprising a power supply and a voltage controller, wherein the small support stand printing device is configured to print a second printing body and the injection barrel is configured to contain the material, and the three dimensional moving platform is configured to move the injection device, such that a distance exists between the pinhead and the carrier unit; the voltage controller is configured to provide a voltage condition output to the pinhead through the power supply, and the movement of the three dimensional moving platform is configured to generate relative movement by the pinhead and the carrier unit.
US Pat. No. 10,889,701

RESIN COMPOSITION AND RESIN MOLDED ARTICLE

Eastman Chemical Company,...

1. A resin composition comprising:a resin (A) having a biomass-derived carbon atom;
a resin (B) incompatible with the resin (A); and
a plasticizer (C),
wherein a content of the resin (A) is larger than a content of the resin (B), and a glass transition temperature Tg(A) of the resin (A) is higher than a glass transition temperature Tg(B) of the resin (B),
wherein a difference (Tg(A)?Tg(A+C)) between the glass transition temperature Tg(A) of the resin (A) and a glass transition temperature Tg(A+C) of a mixture obtained by mixing 10 parts by mass of the plasticizer (C) with 90 parts by mass of the resin (A) is 25° C. to 60° C., and
a difference (Tg(B)?Tg(B+C)) between the glass transition temperature Tg(B) of the resin (B) and a glass transition temperature Tg(B+C) of a mixture obtained by mixing 10 parts by mass of the plasticizer (C) with 90 parts by mass of the resin (B) is 15° C. to 40° C.
US Pat. No. 10,889,702

REINFORCING MATERIAL FOR RUBBER COMPRISING ALUMINOSILICATE PARTICLES AND RUBBER COMPOSITION FOR TIRES COMPRISING THE SAME

LG CHEM, LTD., Seoul (KR...

1. A reinforcing material for rubber comprising amorphous aluminosilicate particles, wherein the aluminosilicate particles are represented by following Chemical Formula 1:[(MaAlxO2x).(SiyO2y)].m(H2O)  [Chemical Formula 1]
wherein, in Chemical Formula 1,
M is an element selected from the group consisting of Li, Na, K, Rb, Cs, Be, Fr, Ca, Zn, and Mg, or an ion thereof;
a?0, x>0, y>0, and m?0;
a/x<1.2; and
3.0 wherein the aluminosilicate particles satisfy the following conditions:
in a data plot obtained by X-ray diffraction (XRD) of the aluminosilicate particles, a full width at half maximum (FWHM) in a 2? range of 23° to 37° is 5° to 7° , and a maximum peak intensity (Imax) is in a 2? range of 23° or more and 25.8° or less, and
wherein a secondary particle size distribution of the aluminosilicate particles has a volume average particle diameter (Dmean)of 1 to 25 ?m, a geometric standard deviation of 1 to 20 ?m, and a 90% cumulative particle diameter (D90) of 1 to 50 ?m, when measured using distilled water.
US Pat. No. 10,889,703

LATEX COMPOSITION FOR DIP-MOLDING, AND MOLDED ARTICLE PREPARED FROM SAME

LG Chem, Ltd.

1. A latex composition for dip-molding comprising:a carboxylic acid-modified nitrile based copolymer latex copolymerized from conjugated diene-based monomers, ethylenically unsaturated nitrile monomers and ethylenically unsaturated acid monomers, and monoglyceride.
US Pat. No. 10,889,704

HALOGENATED ELASTOMERS WITH MOONEY VISCOSITY STABILITY AND METHOD FOR PREPARING SAME

ExxonMobil Chemical Paten...

1. A method of improving Mooney stability of a brominated elastomer, the method comprising:neutralizing a brominated elastomer effluent with a neutralizing agent and water to form a neutralized effluent comprising a hydrocarbon solvent;
removing the hydrocarbon solvent from the neutralized effluent to form a brominated elastomer slurry; and
separating a brominated elastomer from the brominated elastomer slurry,
wherein an amine-functional hindered amine stabilizer (HAS) and an acid scavenger are added i) to the brominated elastomer effluent prior to neutralizing, ii) when neutralizing the brominated elastomer effluent, or iii) to the neutralized effluent prior to removing the hydrocarbon solvent, together or separately, and
wherein the amine-functional HAS comprises a HAS nitrogen atom having a first pKa and the acid scavenger comprises a protonatable atom with a pKa greater than the pKa of the HAS nitrogen atom.
US Pat. No. 10,889,705

CROSSLINKED POLYMER COMPOSITION FOR CABLE ACCESSORIES

BOREALIS AG, Vienna (AT)...

1. A crosslinked polymer composition comprising:a plastomer, wherein the plastomer is a copolymer of ethylene and a C4 to C8 alpha olefin comonomer and wherein the plastomer has a density (according to ISO 1183) in the range of 855 kg/m3 to 890 kg/m3,
wherein the crosslinked polymer composition has:
a Shore A value measured according to ISO 868 of equal to or below 80,
an elongation at break measured according to ISO 527-2 of at least 300%, and
wherein polymers other than the plastomer are absent.
US Pat. No. 10,889,706

POLYPROPYLENE RESIN COMPOSITION

NOF CORPORATION, Tokyo (...

1. A polypropylene resin composition comprising component (A), component (B) and component (C) shown below, wherein a content of the component (A) is from 70 to 90 parts by weight, a content of the component (B) is from 10 to 30 parts by weight, and a content of the component (C) is from 2 to 5 parts by weight, when a total of the content of the component (A) and the content of the component (B) is taken as 100 parts by weight:(A) polypropylene,
(B) talc having an average particle diameter of 1 ?m to 8 ?m,
(C) polyethylene glycol, wherein a molecular weight at a maximum point of refractive index intensity in a chromatogram obtained by gel permeation chromatography using a differential refractometer is from 2,000 to 3,500, and S2/S1 is from 1.3 to 1.6, when a peak area from an elution start point to an elution time corresponding to the maximum point of refractive index intensity is taken as S1 and a peak area from the elution time corresponding to the maximum point of refractive index intensity to an elution end point is taken as S2.
US Pat. No. 10,889,707

GLASS FIBER COMPOSITE MATERIAL COMPOSITION HAVING IMPROVED IMPACT STRENGTH

LOTTE CHEMICAL CORPORATIO...

1. A glass fiber composite material composition comprising: (A) 60-93% by weight of polypropylene; (B) 1-30% by weight of glass fiber sized with a methacryloxysilane-based compound; and (C) 1-10% by weight of a polypropylene resin modified with maleic anhydride and a methacryloxysilane-based compound, wherein the modified polypropylene resin has the maleic anhydride content of 0.5-3 wt % and the methacryloxysilane-based compound content of 0.5-5 wt %, on the basis of 100 wt % of the modified polypropylene resin, and the methacryloxysilane-based compounds are 3-methacryloxypropyltrimethoxysilane or 3-methacryloxypropyltriethoxysilane.
US Pat. No. 10,889,708

POLYMER COMPOSITION FOR CAPS AND CLOSURES

SABIC GLOBAL TECHNOLOGIES...

1. Caps and closures comprising:a high density polyethylene, a polyolefin elastomer, and a polypropylene wherein the amount of high density polyethylene is more than 50% by weight of the total amount of the high density polyethylene, the polyolefin elastomer and the polypropylene,
wherein the total amount of high density polyethylene, polyolefin elastomer and polypropylene is 100% by weight, and
wherein the polyolefin elastomer is an ethylene-alpha olefin copolymer derived from two monomers consisting of ethylene and an alpha olefin containing 4-10 carbon atoms.
US Pat. No. 10,889,709

THERMOPLASTIC RESIN COMPOSITION, INNER LINER AND PNEUMATIC TIRE

THE YOKOHAMA RUBBER CO., ...

1. A thermoplastic resin composition comprising a continuous phase comprising an ethylene-vinyl alcohol copolymer and a polyamide and a dispersed phase comprising a halogenated isomonoolefin-para-alkylstyrene copolymer, wherein the composition comprises from 0.5 to 20 parts by weight of an acylglycerol based on 100 parts by weight of the ethylene-vinyl alcohol copolymer, wherein said acylglycerol consists of triglyceride derived from a fatty acid having 2 to 7 carbon atom and glycerol.
US Pat. No. 10,889,710

RESIN COMPOSITION

MITSUBISHI CHEMICAL CORPO...

1. A resin composition comprising:a polyvinyl alcohol-based resin (A); and
a multimeric aldehyde compound (B),
wherein a content of the multimeric aldehyde compound (B) is 0.5×10?4 to 100×10?4 parts by weight with respect to 100 parts by weight of the polyvinyl alcohol-based resin (A).
US Pat. No. 10,889,711

COMPOSITION

DELTA OF SWEDEN AB, Halm...

1. A modelling compound comprising at least one composition, wherein said composition comprises:a) one or more copolymers of vinyl acetate and at least one other vinyl ester, or at least one homopolymer of vinyl acetate and at least one copolymer of vinyl acetate and at least one other vinyl ester, wherein said other vinyl ester is of the formula H2C?CH—O—CO—R, wherein R is a C2 to C18 branched or straight-chain alkyl group;
b) at least one softener; and
d) at least one filler;
wherein a) is present in an amount of 30 to 95% by weight of components a) and b);
wherein b) is present in an amount of 10 to 70% by weight of components a) and b);
wherein said filler is selected from the group consisting of a sand filler, a glass filler, a polymer filler, and mixtures thereof; and
wherein said polymer filler is a polystyrene, polyolefin, polyester, and/or polyamide filler.
US Pat. No. 10,889,712

STYRENIC BLOCK COPOLYMER-HYPERBRANCHED STYRENIC BLOCK COPOLYMER NETWORKS

THE UNIVERSITY OF AKRON, ...

3. A method of synthesizing a thermoplastic elastomeric network comprising hyperbranched styrenic block copolymers and styrenic block copolymers comprising:initiating living cationic polymerization of monomers, to form polymers having living cationic ends, wherein the step of initiating utilizes 1-(tert-butyl)-3,5-bis(2- chloropropan-2-yl)benzene as the initiator;
adding styrene after the completion of the living cationic polymerization of the monomers, thereby conducting living cationic polymerization of styrene to the living cationic ends of the polymers to form living cationic copolymers having living cationic styrenic ends;
completing the living cationic polymerization of styrene; and
continuing living cationic polymerization conditions after the completion of the living cationic polymerization of the styrene that form the living cationic copolymers, whereby some of the living cationic styrenic ends are crosslinked to phenyl groups of styrene within the copolymers by Friedel-Crafts alkylation, and wherein the step of continuing living cationic polymerization conditions continues for a time period of from about 60 to about 300 minutes prior to termination of the living cationic polymerization conditions, such that a total time period of synthesizing the thermoplastic elastomeric network is from about 240 to about 480 minutes, whereby nominal molecular weight distribution of the living cationic copolymers is increased with time due to the formation of hyperbranched styrenic block copolymers.
US Pat. No. 10,889,713

POLYAMIDE MOULDING COMPOUND AND MOULDED ARTICLES PRODUCED THEREFROM

1. A polyamide moulding compound comprising:(I) 40 to 100% by weight of a mixture made of
(A) 68 to 88% by weight of at least one partially crystalline, aliphatic polyamide and
(B) 12 to 32% by weight of at least one partially crystalline, partially aromatic polyamide, formed from a diamine component (Ba), a dicarboxylic acid component (Bb), and optionally a lactam- and/or ?-amino acid component (Bc), wherein the diamine component (Ba) is present essentially in equimolar amount to the dicarboxylic acid component (Bb), the quantity of lactam- and/or ?-amino acid component (Bc) is 0 to 15% by mol, and the sum of components (Ba) to (Bc) is 100% by mol, wherein the diamine component (Ba) consists of
(Ba1) 62 to 96 mol-parts of 1,6-hexanediamine,
(Ba2) 4 to 38 mol-parts of bis(aminomethyl)cyclohexane, and
(Ba3) 0 to 30 mol-parts of one or more cycloaliphatic diamines, different from (Ba2), wherein the sum of (Ba2) and (Ba3) is 4 to 38 mol-parts and the sum of (Ba1), (Ba2) and (Ba3) is 100 mol-parts,
 the dicarboxylic acid component (Bb) consists of
(Bb1) 64 to 100 mol-parts of terephthalic acid,
(Bb2) 0 to 18 mol-parts of isophthalic acid, and
(Bb3) 0 to 18 mol-parts of one or more aliphatic dicarboxylic acids with 6 to 18 C atoms, wherein the sum of (Bb1), (Bb2) and (Bb3) is 100 mol-parts, and
the lactam- and/or ?-amino acid component (Bc) consists of one or more lactams and/or ?-amino acids, wherein the sum of the lactams and/or ?-amino acids is 100 mol-parts, and
the proportions of (A) and (B) are related to the sum of the polyamides (A) and (B) and constitute in total 100% by weight of the mixture,
(II) 0-60% by weight of fibrous reinforcing materials;
(III) 0-30% by weight of particulate fillers, different from (II) and (IV) to (VI);
(IV) 0-20% by weight of impact modifiers;
(V) 0-2.0% by weight of heat stabilisers;
(VI) 0-6% by weight of auxiliary materials and/or additives different from (II)-(V);
the sum of components (I)-(VI) constituting 100% by weight of the polyamide moulding compound.
US Pat. No. 10,889,714

POLYPHENYLENE SULFIDE RESIN COMPOSITION AND MANUFACTURING METHOD OF THE SAME

Toray Industries, Inc., ...

1. A polyphenylene sulfide resin composition obtained by mixing a polyphenylene sulfide resin (a), a fluororesin (b) and an organosilane compound (c), whereinwhen a resin phase-separated structure of a molded product formed from the polyphenylene sulfide resin composition is observed by an electron microscope, the component (a) forms a continuous phase, the component (b) forms a primary dispersed phase having a number-average dispersion diameter of not greater than 1 ?m, and a secondary dispersed phase of the component (a) is included in the primary dispersed phase of the component (b).
US Pat. No. 10,890,226

FIBER FOR TRIBOLOGICAL APPLICATIONS

Tribotecc GmbH, Vienna (...

1. A fiber for tribological applications wherein said fiber is surface-treated with at least one solid lubricant,said fiber being a metal fiber, a ceramic fiber, a natural fiber, a polymeric fiber, a cellulose fiber, an aramid fiber, a plastic fiber, a glass fiber, a nanofiber, or a carbon fiber, and
the solid lubricant being formed of one or more of SnS, SnS2, MoS2, Bi2S3, ZnS, WS2, CuFeS2, FeS, CuS, Cu2S, MnS, Sb2S3, TiS2, sulfides of Cr/Co/Ni, Sn2S3, MoS3, WS3, Fe1-xS, MnS2, Sb2S5, ZrS2, CaS, MgS, sulfides of La, multi-phased metal sulfides, or mixtures thereof;
wherein said solid lubricant is chemically bound to said fiber through sulfidization;
wherein the amount of the at least one solid lubricant is at least 3% by weight.
US Pat. No. 10,889,715

POLYMER COMPOSITION COMPRISING CROSSLINKED SILICONES WITH EXCHANGEABLE CROSSLINKING POINTS, PREPARATION METHOD AND USES

ECOLE SUPERIEURE DE PHYSI...

1. A silicone composition comprising (a) crosslinked polymers comprising consecutive —Si—O— units containing exchangeable pendant bonds and exchangeable crosslinking points, that are exchangeable by aldehyde-imine exchange reactions and/or by imine-imine exchange reactions and/or by imine-primary amine exchange reactions, obtained by crosslinking of linear or branched polymers comprising consecutive —Si—O— units and (b) monofunctional free aldehydes and/or monofunctional free imines and/or monofunctional free primary amines.
US Pat. No. 10,889,716

BINDERS CONTAINING AN ALDEHYDE-BASED RESIN AND AN ISOCYANATE-BASED RESIN AND METHODS FOR MAKING COMPOSITE LIGNOCELLULOSE PRODUCTS THEREFROM

Georgia-Pacific Chemicals...

1. A binder for making composite lignocellulose products, comprising:about 70 wt % to about 99.7 wt % of an aldehyde-based resin;
about 0.3 wt % to about 30 wt % of an isocyanate-based resin;
about 10 wt % to about 63 wt % of an extender; and
about 145 wt % to about 230 wt % of water, wherein the weight percent values of the aldehyde-based resin, the isocyanate-based resin, the extender, and the water are based on a combined solids weight of the aldehyde-based resin and the isocyanate-based resin,
wherein the binder comprises about 21.75 wt % to about 29.7 wt % of aldehyde-based resin solids, based on a total weight of the binder, and
wherein the binder has a viscosity of about 200 cP to about 3,500 cP at a temperature of about 25° C. for at least the first 24 hours after formation of the binder.
US Pat. No. 10,889,720

PHOSPHOR INTEGRATED DOTS NANOPARTICLES AND LABELING AGENT USING SAME

KONICA MINOLTA, INC., To...

1. Phosphor integrated dots nanoparticles comprising a hydrophobic fluorescent substance accumulated therein and a thermosetting resin as a matrix,said thermosetting resin containing a structural unit formed from a raw material containing a hydrophobic substituent,
said hydrophobic fluorescent substance being accumulated in said nanoparticles at least by hydrophobic interaction with the hydrophobic substituent of said thermosetting resin.
US Pat. No. 10,889,722

COATING POWDER FORMULATION

1. A powder coating formulation, comprising at least one partially crystalline thermoplastic unsaturated polyester (A), at least one thermoplastic allyl prepolymer (B), which is copolymerizable with said polyester, and a thermal initiation system (C), including at least one thermal initiator, wherein the allyl prepolymer (B) has a weight average molar mass greater than 5000 g/mol, and/or has a viscosity of 30 mPas to 200 mPas, and wherein the unsaturated polyester (A) has a melting point of between 90 and 120° C.
US Pat. No. 10,889,723

SYNERGISTIC CORROSION INHIBITOR COMPOSITIONS

The United States of Amer...

1. Synergistic corrosion-resistant inhibitor composition consisting essentially of combinations of at least one metal polycarboxylate and 1.0 to 50 percent by weight of the composition of lithium phosphate wherein the metal of the polycarboxylate is selected from the group consisting of Groups IIa, IIIb, IVb, Vb, VIb, VIII, Ib, IIb and IIIa of the Periodic Table.
US Pat. No. 10,889,728

SILICONE MIST INHIBITOR

SHIN-ETSU CHEMICAL CO., L...

1. A solventless silicone composition comprising an organopolysiloxane having a viscosity at 25 degrees C. of 25 to 50,000 mPa·s, wherein the solventless silicone composition further comprises a silicone mist inhibitor in an amount of 0.1 to 10 parts by mass, relative to 100 parts by mass of said organopolysiloxane,wherein the silicone mist inhibitor comprises at least one selected from (i) silicone elastomer particles and (ii) silicone elastomer particles whose surfaces are covered with a polyorganosilsesquioxane, and optionally comprises polyorganosilsesquioxane particles, wherein the particles have a volume average particle size of 100 to 4000 nm, and
wherein the silicone elastomer particles of (i) and (ii) are a cured product of an organopolysiloxane having a linear organosiloxane block represented by —(R12SiO2/2)n—, wherein R1 is a substituted or unsubstituted monovalent hydrocarbon group having 1 to 30 carbon atoms and n is an integer of from 5 to 5,000, and have rubber hardness of 20 to 80, as determined with a type A durometer according to the Japanese Industrial Standards (JIS) K 6253.
US Pat. No. 10,892,034

USE OF HOMOLOGY DIRECT REPAIR TO RECORD TIMING OF A MOLECULAR EVENT

Microsoft Technology Lice...

1. A system for creating a temporal record in a polynucleotide log, the system comprising:a gene oscillator configured to create a signal at a periodicity;
a double-stranded polynucleotide having a target site;
an enzyme configured to create a double strand break (DSB) in the double-stranded polynucleotide at a cut site in the target site; and
a gene encoding a homology directed repair (HDR) template configured for insertion into the cut site, the HDR template including a middle portion that is not homologous to the target site, the gene expressing the HDR template based on presence of the signal relative to a threshold level,
wherein the HDR template is configured for incorporation into the double-stranded polynucleotide with a frequency that is based on the periodicity,
wherein the middle portion comprises a second cut site and the system further comprises a second enzyme configured to create a DSB at the second cut site and a second gene encoding a second HDR configured for insertion into the second cut site, the second gene configured to express the HDR template in response to a second signal generated by a molecular event.
US Pat. No. 10,888,960

SOLDER ALLOY AND RESIN FLUX CORED SOLDER

KOKI Company Limited, To...

1. A solder alloy consisting of 0.01 mass % or more and 0.1 mass % or less of Fe, 0.01 mass % or more and 0.015 mass % or less of Co, 0.1 mass % or more and 4.5 mass % or less of Ag, 0.1 mass % or more and 0.8 mass % or less of Cu, and the balance being Sn.
US Pat. No. 10,892,035

METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS

Sequenom, Inc., San Dieg...

1. A method for partitioning genomic regions of a reference genome comprising:a) obtaining nucleotide sequence reads from a plurality of samples comprising a mixture of maternal and fetal circulating cell-free nucleic acid;
b) mapping the nucleotide sequence reads to the reference genome to obtain a training set of nucleotide sequence reads from the plurality of samples, wherein the training set of nucleotide sequences comprises from thousands to millions of sequence reads;
c) determining sequencing coverage variability across the reference genome by quantification of the sequence reads of the training set of nucleotide sequence reads;
d) selecting an initial portion length for portions of the genomic regions based on features of the training set of nucleotide sequence reads;
e) partitioning at least two genomic regions into a number of portions according to the initial portion length in (d), wherein the at least two genomic regions comprise a first genomic region and a second genomic region;
f) comparing the sequencing coverage variability determined in (c) for the first genomic region to the sequencing coverage variability determined in (c) for the second genomic region, wherein the comparing comprises calculating a proportionality factor comprising a ratio between the sequencing coverage variability of the first region and the sequencing coverage variability of the second region;
g) recalculating the number of portions for the first genomic region and the second genomic region according to the proportionality factor;
h) determining an optimized portion length for the first genomic region and the second genomic region based on the recalculated number of portions; and
i) re-partitioning the first genomic region and the second genomic region into a plurality of portions according to the optimized portion length determined in (h).
US Pat. No. 10,892,036

SYSTEMS AND METHODS FOR DETERMINING THE IDENTITY OF ALLELES FROM GENOMIC SEQUENCING DATA

Verily Life Sciences LLC,...

1. A method for identifying an allele within a genomic sample, the method comprising:obtaining, by a computing device, a plurality of paired-end fragments from a genomic sample;
extracting, by the computing device, a group of nucleotide substrings from each pair-end fragment;
comparing, by the computing device, each nucleotide substring within the group of nucleotide substrings to reference nucleotide substrings within an index that provides a mapping between each reference nucleotide substring and an allele that contains the reference nucleotide substring;
identifying, by the computing device, for each nucleotide substring, a subset of alleles that contain the nucleotide substring based on the comparing and the mapping;
identifying, by the computing device, alleles that are present in two or more of the identified subsets of alleles;
determining, by the computing device, for each identified allele, a probability that the genomic sample comprises the allele based on a number of the plurality of paired-end fragments that include a nucleotide substring from the allele; and
identifying, by the computing device, an allele is within the genomic sample when the allele has a greatest determined probability compared to that of the determined probabilities for the identified alleles.
US Pat. No. 10,889,731

DURABLE AQUEOUS COMPOSITIONS FOR USE IN MAKING TRAFFIC MARKINGS HAVING GOOD DIRT PICKUP RESISTANCE AND TRAFFIC MARKINGS MADE THEREWITH

Rohm and Haas Company, P...

1. An aqueous composition for use in traffic markings comprising (i) from 5 to 30 wt. % as solids, based on the total weight of the aqueous composition, of one or more vinyl or acrylic emulsion polymers chosen from single stage and multi-stage emulsion polymers, the polymer or at least one stage of the one or more multi-stage emulsion polymers having a calculated glass transition temperature (Tg) of from ?25 to 0° C., and having a calculated Hansch parameter of from 1.4 to 2.25 (ii) one or more fillers, extenders and/or pigments, wherein the composition has a percent pigment volume concentration (% PVC) of from 40 to 80%, and an aminosilane.
US Pat. No. 10,892,038

METHOD TO USE GENE EXPRESSION TO DETERMINE LIKELIHOOD OF CLINICAL OUTCOME OF RENAL CANCER

Genomic Health, Inc., Re...

1. A method of analyzing the expression of RNA transcripts of genes in a human renal cancer patient, comprising:measuring a level of an RNA transcript, in a renal tumor sample from the patient, of a panel of genes consisting of:
(a) a set of genes consisting of one or more genes selected from: YBX1, XIAP, WWOX, VWF, VEGFA, VCAM1, USP34, UMOD, UGCG, UBB, UBA3, TYMS, TUSC4, TSPAN7, TSC2, TSC1, TP53, TOP2B, TNFSF12, TNFSF10, TNFRSF11B, TNFRSF10D, TNFRSF10B, TNFAIP6, TMEM47, TM2M27, TLR3, TIMP3, TIMP2, THBS1, TGFBR2, IGF1R, IF127, ID3, ID2, ID1, ICAM2, HYAL2, HYAL1, HSPG2, HSD11B2, HPN, HPCAL1, HMGB1, HLA-DPB1, HIF1AN, HDAC1, HAVCR1, HADH, GZMA, GSTP1, GSTM3, GSTM1, GRB7, GPX3, GJA1, GFRA1, GCLC, GBP2, GATM, GATA3, FOS, TGFBR1, TGFB2, TGFA, TEK, TCF4, TAP1, TAGLN, TACSTD2, SUCLG1, STK11, STAT5B, STAT5A, STATS, SPRY1, SPARCL1, SPARC, SOD1, SNRK, SNAI1, SMAD4, SMAD2, SLC34A1, SLC22A6, SKIL, SHANKS, SGK1, SFRP1, SEMA3F, SELENBP1, SDPR, SDHA, SCNN1A, FOLR1, FLT4, FLT3LG, FLT1, FILIP1, FIGF, FHL1, FHIT, FH, FGFR2, FGFR1, FGF2, FGF1, FDPS, FBXW7, FAS, FABP1, ESRRG, ERG, ERCC1, ERBB3, ERBB2, EPHB4, EPHA2, EPAS1, ENPP2, ENPEP, ENG, EMP1, EMCN, ELTD1, EIF2C1, SCN4B, RPTOR, RPS6KB1, RPS6KA1, RPS23, ROCK2, ROCK1, RIPK1, RHOC, RHOB, RHOA, RGS5, RERGL, RELA, RB1, RASSF1, BARB, RALBP1, RAF1, PTPRG, PTPRB, PTN, PTK2, PTH1R, PTEN, PSMB9, PSMB8, PRSS8, PRPS2, PRKCH, PPP2CA, EGR1, EGLN3, EGFR, EFNB2, EFNB1, EEF1A1, EDNRB, EDN2, EDN1, EBAG9, DUSP1, DPYS, DPEP1, DLL4, DLC1, DKFZP564O0823, DICER1, DIAPH1, DIABLO, DHPS, DET1, DEFB1, DDC, DCXR, DAPK1, CYR61, CYP3A4, CXCL9, CXCL12, CX3CR1, CX3CL1, PPARG, PPAP2B, PLG, PLAT, PLA2G4C, PIK3CA, PIK3C2B, PFKP, PECAM1, PDZK3, PDZK1, PDGFRB, PDGFD, PDGFC, PDGFB, PDGFA, PCK1, PCCA, PARD6A, PAK1, PAH, OGG1, NUDT6, NRG1, NPR1, NPM1, NOTCH3, NOTCH2, NOTCH1, NOS3, NOS2, NOL3, NFX1, CUL1, CUBN, CTSS, CTSH, CTNNB1, CTNNA1, CTGF, CSF1R, CSF1, CRADD, COL4A2, COL18A1, CLU, CLDN7, CLDN10, CLCNKB, CFLAR, CEACAM1, CDKN1B, CDKN1A, CDH6, CDH5, CDH16, CDH13, CD4, CD36, CD34, CCR7, CCR4, CCND1, CCL4, CCL2, CAT, NFKB1, NFATC2, NFAT5, MYRIP, MYH11, MYC, MVP, MUC1, MTOR, MSH3, MSH2, MLST8, MIF, MICA, MGMT, MCM3, MCAM, MARCKS, MAPK3, MAPK1, MAP4, MAP2K3, MAP2K1, MAL2, MAL, LYZ, LTF, LRP2, LMO2, LDB2, LDB1, LAMA4, KRT7, CASP6, CASP10, CALD1, CA9, CA2, C7, C2 orf40, C13orf15, BUB3, BTRC, BIRC2, BIN1, BGN, BCL2L12, BCL2L1, BCL2, BBC3, BAG1, BAD, ATP6V1B1, ASS1, ARRB1, ARHGDIB, AQP1, APOLD1, APC, ANXA4, ANXA1, ANTXR1, ANGPTL4, ANGPTL3, ANGPT1, ALDOB, KRAS, KL, KITLG, KIT, KDR, KCNJ15, KAT5, JUP, JUN, JAG1, ITGB1, ITGA7, ITGA6, ITGA4, ITGA3, IQGAP2, INSR, IMPS, IL6ST, IL15, IGFBP6, IGFBP3, IGFBP2, ALDH6A1, ALDH4A1, AKT3, AKT2, AKT1, AIF1, AHR, AGTR1, ADH1B, ADFP, ADD1, ADAMTS5, ADAMTS1, ACE2, ACADSB, ABCG2, ABCC4, ABCC3, ABCC1, ABCB1, ABAT, AAMP, and A2M;
(b) a set of genes consisting of one or more genes selected from: WT1, VTN, VDR, VCAN, UBE2T, TPX2, TOP2A, TK1, TIMP1, TGFBI, SQSTM1, SPP1, SPHK1, SLC7A5, SLC2A1, SLC16A3, SLC13A3, SHC1, SFN, SERPINA5, SEMA3C, SAA2, S100A1, RRM2, RPLP1, PTTG1, PTGS2, PLAUR, PF4, PCSK6, MYBL2, MT1X, MMP9, LGALS1, LAMBS, LAMB1, L1CAM, IL8, IL6, ICAM1, HIST1H1D, FN1, F3, F2, ESPL1, EPHB2, EPHB1, ENO2, EIF4EBP1, CXCR4, CXCL1, CTSB, CRP, CP, COL7A1, COL1A1, CHEK1, CENPF, CD82, CD44_s, CCNE1, CCNB1, CCL20, CA12, C3, BUB1, MMP7, MMP14, MKI67, MGST1, MDK, LOX, LMNB1, LIMK1, BIRC5, BIRC3, BCL2A1, AURKA, ANXA2, ALOX5, ADAM8, and ABCC2;
(c) a set of genes consisting of one or more genes selected from: ACE2, ADD1, ALDOB, ANGPTL3, APOLD1, AQP1, NUDT6, CASP10, CAV2, CCL4, CCL5, CCR2, CCR4, CCR7, CD4, CD8A, CEACAM1, CFLAR, CTSS, CX3CL1, CXCL10, CXCL9, CXCR6, DAPK1, DDC, DLC1, C2 orf40, EDNRB, EMCN, EPAS1, FAS, FH, GATA3, GZMA, HLA-DPB1, HSPG2, ICAM2, ICAM3, ID1, IGF1R, IL15, IQGAP2, KLRK1, LDB2, LRP2, LTF, MAP4, ABCC1, NOS3, PIK3C2B, PLA2G4C, PPAP2B, PRCC, PRKCB, PRKCH, PRSS8, PSMB9, PTPRB, RGS5, SDPR, SELE, SGK1, SHANKS, SNRK, TEK, TGFBR2, TIMP3, TMEM27, TSPAN7, UBB, and WWOX; and
(d) a set of consisting of one or more genes selected from: BIRC2, BUB1, CCNB1, ENO2, ITGB1, ITGB5, LAMB1, MMP14, MMP9, PSMA7, RUNX1, SPHK1, SPP1, SQSTM1, TPX2, TUBBA2, and VCAN;
wherein the gene(s) of the sets do not overlap, and wherein one or more of AAMP, RPS23, SDHA, UBB, and RPLP1 is a member of the panel.
US Pat. No. 10,889,733

COATING COMPOSITION FOR FORMING SCRATCH-RESISTANT LAYER HAVING HIGH STRENGTH FOR AUTOMOBILE EXTERIOR AND METHOD FOR COATING AUTOMOBILE EXTERIOR USING THE SAME

NOROO BEE Chemical Co., L...

1. A coating composition for forming a scratch-resistant layer having a high strength for automobile exterior, comprising:5 wt % to 20 wt % of a caprolactone-modified hyperbranched polyester polyol, the caprolactone-modified hyperbranched polyester polyol obtained from polyhydric alcohol including caprolactone triol;
30 wt % to 50 wt % of a first acrylic resin, the first acrylic resin having a hydroxyl group;
15 wt % to 25 wt % of a second acrylic resin, the second acrylic resin having a hydroxyl group and having a glass transition temperature higher than that of the first acrylic resin; and
20 wt % to 40 wt % of a solvent,
wherein the first acrylic resin has a solid content of 60% to 70%, a weight average molecular weight of 5,000 to 12,000, and a glass transition temperature of 10° C. to 20° C.
US Pat. No. 10,889,734

STRETCHABLE POLYMER THICK FILM COMPOSITIONS FOR THERMOPLASTIC SUBSTRATES AND WEARABLES ELECTRONICS

DUPONT ELECTRONICS, INC.,...

1. An article containing an electrical circuit comprising an element formed from a polymer thick film composition, said polymer thick film composition comprising a functional component and an organic medium, wherein said element is a conductor and wherein said functional component is silver powder in combination with silver chloride powder and said polymer thick film composition is a polymer thick film conductor composition comprising:(a) silver powder in combination with silver chloride powder; and
(b) the organic medium comprising 5-50 wt % thermoplastic polyurethane resin dissolved in an organic solvent, said thermoplastic polyurethane resin having a percent elongation of at least 200% and a tensile stress necessary to achieve 100% elongation of less than 1000 psi, wherein the weight percent is based on the total weight of said organic medium; wherein
said composition is dried to remove said solvent and form said conductor.
US Pat. No. 10,892,040

METHOD FOR EVALUATING A SET OF MEASUREMENT DATA FROM AN ORAL GLUCOSE TOLERANCE TEST

ROCHE DIABETES CARE, INC....

1. A method for treating a patient comprising:obtaining a set of measurement data from an oral glucose tolerance test administered to a patient, whereby the set of measurement data includes a series of measurement data of the glucose concentration;
obtaining at least one series of measurement data of a further analyte concentration;
calculating, by at least one computing device, a similarity measure that quantifies the similarity between a time profile of the measurement data of the glucose concentration and a corresponding glucose reference profile, wherein the calculation of the similarity measure uses the series of measurement data of the glucose concentration and one each of several predefined glucose reference profiles;
calculating, by the at least one computing device, one value each of a further similarity measure that quantifies the similarity between the profile of the series of measurement data of the further analyte concentration and the corresponding further analyte sample profile, wherein the calculation of one value each of a further similarity measure uses the series of measurement data of the further analyte concentration and one each of several predefined further analyte reference profiles, wherein the data set of measurement data is represented by a point in a vector space that comprises coordinate axes that are formed by the similarity measures, whereby the coordinates of said point contain the calculated values of the similarity measures;
evaluating, by the least one computing device, the position of the point with respect to reference points, which each represent a defined state of health, in order to calculate a parameter that specifies the state of the glucose metabolism of the patient;
determining the disease stage of the patient;
determining a course of treatment for the patient from the determined disease stage; and
treating the patient using the determined course of treatment.
US Pat. No. 10,889,736

LOW VOC POLYMERS WITH RELEASE PROPERTIES

OMNOVA Solutions Inc., B...

1. A release polymer comprising at least 67 mole percent mer units that comprise a pendent group that comprises at least two (thio)carbonyl moieties, the C atom of at least one of said (thio)carbonyl moieties being bonded to two additional heteroatoms, one of said additional heteroatoms being a nitrogen atom and the other being selected from O, S and N, said release polymer exhibiting less than 0.5 parts per million volatile organic chemicals when subjected to standard analytical testing procedures for such chemicals.
US Pat. No. 10,889,737

DUAL CURING OPTICALLY TRANSPARENT ADHESIVE COMPOSITIONS

1. An adhesive composition comprising:a photo- and/or heat-curable polyolefin-based oligomer;
a moisture-curable polyolefin-based oligomer;
a curative package to trigger and/or accelerate cure of the oligomer(s) under appropriate cure conditions; and
at least one polyolefin-based polyurethane that is not reactive under the cure conditions with the photo- and/or heat-curable polyolefin-based oligomer or the moisture-curable polyolefin-based oligomer, represented by the formula:
HO—U—P—U—OHwhere U comprises a urethane or urea linkage, and P comprises a polyolefin backbone.
US Pat. No. 10,889,738

ROOM TEMPERATURE CURABLE COMPOSITIONS

Dow Silicones Corporation...

1. A silicone room temperature curable sealant/adhesive composition comprising:(A) at least 50% by weight of one or more organopolysiloxanes selected from:
(i) (R?O)3-a(R)aSi—Z—(Si(R)2—O)X—Si(R)2—Z—Si(OR?)3-a(R)a where each R is free of aliphatic unsaturation and is independently selected from the group consisting of monovalent hydrocarbon, monovalent halohydrocarbon, and monovalent cyanoalkyl radicals having from 1 to 18 carbon atoms, each R? is independently a monovalent hydrocarbon group having 1 to 6 carbon atoms, Z is a divalent hydrocarbon radical or combination of divalent hydrocarbon radicals and siloxane radicals, a is 0 or 1, and x is of a value such that component (A)(i) has a viscosity of from 0.5 to 3000 Pas at 25° C.;
(ii) alpha, omega-diorganopolysiloxane of the formula
(HO)3-b(R)bSi—O—(Si(R)2—O)y—Si(OH)3-b(R)b
where each R is free of aliphatic unsaturation and is independently selected from the group consisting of monovalent hydrocarbon, monovalent halohydrocarbon, and monovalent cyanoalkyl radicals having from 1 to 18 carbon atoms, b is 0, 1 or 2, and y is of a value such that component (A)(ii) has a viscosity of from 0.5 to 3000 Pas at 25° C. and a number average molecular weight (Mn) of from 1000 to 1000000; or
(iii) mixtures of the above;
(B) 5 to 35% by weight of a hydrophilic material comprising
(B)(iii) polymers containing ionisable groups;
(C) 0.5 to 7.5% by weight of a cross-linker selected from a silane or siloxane cross linker containing at least two alkoxy or alkenyloxy groups, or silyl functional molecules having at least two silyl groups, each silyl group containing at least one alkoxy or alkenyloxy group;
(D) 0.5 to 5% by weight titanate or zirconate catalyst; and
(E) optionally, one or more ingredients selected from fillers, co-catalysts, rheological modifiers, plasticisers, adhesion promoters, compatibilizers, pigments, heat stabilizers, flame retardants, UV stabilizers, chain extenders, electrically and/or heat conductive fillers, and/or fungicides/biocides;
wherein the total % by weight of components (A)+(B)+(C)+(D)+(E) is 100%; and
wherein the hydrophilic material is selected from homopolymers and copolymers comprising vinylsulphonic, styrenesulphonic, naphthalenesulphonic or acrylamidoalkylsulphonic units and their salts and also copolymers thereof with an unsaturated comonomer.
US Pat. No. 10,889,740

AZEOTROPIC AND AZEOTROPE-LIKE COMPOSITION

Zhejiang Quhua Fluor-Chem...

1. An azeotropic or azeotrope-like composition, comprising 80-95 wt % of (E)-1,14,4,4-hexafluoro-2-butene, 1-19 wt % of (E)-1-chloro-3,3,3-trifluoropropene and 1-10 wt % of 1,1,1,2,3,3-hexafluoropropane, wherein the composition has a boiling point of 8.5° C.±0.5° C. at a pressure of 14 psia±0.5 psia.
US Pat. No. 10,889,741

FLUOROCARBON RESIN COMPOSITION AND PREPREG AND COPPER FOIL SUBSTRATE USING THE SAME

NAN YA PLASTICS CORPORATI...

1. A copper foil substrate, prepared by pressing a fluorocarbon resin prepreg as a substrate against a copper foil attached on the upper surface and a copper foil attached on the lower surface thereof at a temperature of 350° C. and a pressure of 50 kg/cm2 and then cooling down the fluorocarbon resin prepreg to room temperature through a first cooling process and a second cooling process, wherein in the first cooling process, the fluorocarbon resin prepreg is cooled down from 350° C. to 250° C. at a cooling rate of 1 to 4° C./min, and in the second cooling process, the fluorocarbon resin prepreg is cooled down from 250° C. to room temperature at a cooling rate of 10° C./min,wherein the fluorocarbon resin prepreg is prepared by impregnation-coating a fiberglass cloth as a substrate with a fluorocarbon resin composition, wherein after the fiberglass cloth is impregnated in the fluorocarbon resin composition prepreg, the fiberglass cloth impregnated with the prepreg is fed into a furnace for drying at 80 to 120° C., baking at 200 to 240° C. and sintering at 340 to 360° C., and wherein a crystallinity of the fluorocarbon resin composition is within a range of 69.5% to 78.2%, and a dielectric loss of the copper foil substrate at a frequency of 10 GHz is within a range of 0.0013 to 0.0028,
wherein the fluorocarbon resin composition includes, on the basis of the total weight of the fluorocarbon resin composition being 100 wt %:
(1) a polytetrafluoroethylene (PTFE) resin, accounting for 10 to 90 wt %;
(2) a fluorine-containing copolymer, accounting for 1 to 10 wt % and selected from the group consisting of one or a combination of more of poly fluoroalkoxy (PFA) and fluorinated ethylene propylene (FEP);
(3) low molecular-weight PTFE micro-powders, accounting, for 5 to 50 wt %, the molecular weight of the low molecular-weight PTFE micro-powders being 2000 to 200000, wherein an average particle diameter of the low molecular-weight PTFE micro-powders is 1 to 10 ?m; and
(4) inorganic powders, accounting for 15 to 80 wt %, wherein an average particle diameter of the inorganic powders is 0.01 to 50 ?m, and wherein the inorganic powders is one ore more selected from the group consisting of silicon dioxide (SiO2), titanium dioxide (TiO2), aluminum hydroxide (Al(OH)3), alumina (Al2O3), magnesium hydroxide (Mg(OH)2), magnesium oxide (MgO), calcium carbonate (CaCO3), boron oxide (B2O3), calcium oxide (CaO), strontium titanate (SrTiO3), barium titanate (BaTiO3), calcium titanate (CaTiO3), magnesium titanate (2MgO.TiO2), boron nitride (BN), aluminum nitride (AlN), silicon carbide (SiC), cerium oxide (CeO2) and fume silica.
US Pat. No. 10,888,719

ACTIVE SUBSTANCE COMBINATION OF CREATINE AND/OR CREATININE AND PHENOXYETHANOL

BEIERSDORF AG, Hamburg (...

1. A cosmetic or dermatological O/W emulsion which comprises(I) at least one of creatine and a creatine derivative selected from creatine phosphate, creatine sulfate, creatine acetate, creatine ascorbate, and an ester of creatine and a mono- or polyfunctional alcohol;
(II) phenoxyethanol;
(III) at least one of (i) creatinine and (ii) glycerin;
wherein the emulsion further comprises carnitine and/or a derivative thereof.
US Pat. No. 10,890,513

CELL-HOLDING SUBSTRATE HOLDER FOR PREPARING OBSERVATION SPECIMEN, KIT INCLUDING SAME, AND OBSERVATION SPECIMEN PREPARATION METHOD

NATIONAL UNIVERSITY CORPO...

1. A cell-holding substrate holder for preparing an observation specimen, said holder comprising:(1) a support plate having a cell-holding substrate arrangement portion having a window portion through which water can pass; and
(2) a removable sandwiching plate which has a window portion through which water can pass, and is capable of working in conjunction with the support plate to sandwich and fix a cell-holding substrate in the cell-holding substrate arrangement portion,
wherein the support plate has hollows on both sides of the window portion, and the sandwiching plate is a cover plate having claws which can be fitted into both of the hollows.
US Pat. No. 10,888,720

GENTIOPICROSIDE FREE GENTIANA EXTRACT

DSM IP ASSETS B.V., Heer...

1. A method for combatting skin aging by reducing wrinkles, inducing collagen synthesis, and/or reducing intracellular reactive oxygen species production in skin of a patient in need thereof, wherein the method comprises topically applying to the skin of the patient an effective amount of a cosmetic composition comprised of a substantially gentiopicroside-free extract of Gentiana acaulis and/or Gentiana septemfida, and observing the skin aging combatting effects thereof, wherein the substantially gentiopicroside-free extract comprises gentiopicral hydrolyzed from gentiopicroside.
US Pat. No. 10,889,748

PROCESS FOR PREPARING DIBENZYLAMINE QUATERNARY AMMONIUM SALT HIGH-TEMPERATURE RESISTANT CORROSION INHIBITOR AND APPLICATIONS THEREOF

SOUTHWEST PETROLEUM UNIVE...

1. A process for preparing a dibenzylamine quaternary ammonium salt high-temperature resistant corrosion inhibitor, comprising the following steps in sequence:(1) dissolve amine reagents selected from the group consisting of benzylamine, phenethylamine, morpholine or indole in an organic solvent, slowly add epichlorohydrin dropwise, stir to react at a room temperature for 12-14 hours, and then distill under a reduced pressure, and wash to obtain an intermediate I;
(2) dissolve the intermediate I in an organic solvent, add dibenzylamine, then add an acid binding agent, warm to 60-80° C. to react for 14 to 16 hours, after cooling to room temperature, perform filtration, extraction and distillation under a reduced pressure to obtain an intermediate II;
(3) dissolve the intermediate II in an organic solvent, add quaternizing reagent, then warm to 80-110° C. to react for 12 to 15 hours, after cooling to room temperature, perform filtration, extraction and distillation under a reduced pressure to obtain the dibenzylamine quaternary ammonium salt high-temperature resistant corrosion inhibitor.
US Pat. No. 10,889,751

RESERVOIR STIMULATION BY ENERGETIC CHEMISTRY

Liberty Oilfield Services...

1. A self-initiating, self-reactive treatment fluid for treating a hydrocarbon-bearing reservoir in a formation, comprising an aqueous solution comprising: (a) an ammonium salt capable of being exothermally oxidized to produce heat and nitrogen gas; (b) an oxidizing agent capable of oxidizing the ammonium salt; and (c) a free tertiary amine salt or a compound which reacts to form a free tertiary amine salt in situ; (d) a low molecular weight carboxylic acid; and (e) a high salinity brine containing divalent ions comprising Ca2+ and/or Mg2+; and (f) optionally, a surfactant.